{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Asset list successfully imported\n",
      "Fetching data from: https://clinicaltrials.gov/api/v2/studies?query.term=Bitopertin&pageSize=100\n",
      "Fetching data from: https://clinicaltrials.gov/api/v2/studies?query.term=GSBR-1290&pageSize=100\n",
      "Fetching data from: https://clinicaltrials.gov/api/v2/studies?query.term=RP-1&pageSize=100\n",
      "Fetching data from: https://clinicaltrials.gov/api/v2/studies?query.term=Ritlecitinib&pageSize=100\n",
      "Fetching data from: https://clinicaltrials.gov/api/v2/studies?query.term=MK-0616&pageSize=100\n",
      "Fetching data from: https://clinicaltrials.gov/api/v2/studies?query.term=Retatrutide&pageSize=100\n",
      "Historic clinical trials data recognized and reconciling changes from historic file and new trial updates.\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead tr th {\n",
       "        text-align: left;\n",
       "    }\n",
       "\n",
       "    .dataframe thead tr:last-of-type th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th></th>\n",
       "      <th colspan=\"2\" halign=\"left\">Asset</th>\n",
       "      <th colspan=\"2\" halign=\"left\">Title</th>\n",
       "      <th colspan=\"2\" halign=\"left\">Lead Sponsor</th>\n",
       "      <th colspan=\"2\" halign=\"left\">Acronym</th>\n",
       "      <th colspan=\"2\" halign=\"left\">Overall Status</th>\n",
       "      <th>...</th>\n",
       "      <th colspan=\"2\" halign=\"left\">Primary Completion Date</th>\n",
       "      <th colspan=\"2\" halign=\"left\">Study First Post Date</th>\n",
       "      <th colspan=\"2\" halign=\"left\">Last Update Post Date</th>\n",
       "      <th colspan=\"2\" halign=\"left\">Study Type</th>\n",
       "      <th colspan=\"2\" halign=\"left\">Phases</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th></th>\n",
       "      <th>Old CT Data</th>\n",
       "      <th>New CT Data</th>\n",
       "      <th>Old CT Data</th>\n",
       "      <th>New CT Data</th>\n",
       "      <th>Old CT Data</th>\n",
       "      <th>New CT Data</th>\n",
       "      <th>Old CT Data</th>\n",
       "      <th>New CT Data</th>\n",
       "      <th>Old CT Data</th>\n",
       "      <th>New CT Data</th>\n",
       "      <th>...</th>\n",
       "      <th>Old CT Data</th>\n",
       "      <th>New CT Data</th>\n",
       "      <th>Old CT Data</th>\n",
       "      <th>New CT Data</th>\n",
       "      <th>Old CT Data</th>\n",
       "      <th>New CT Data</th>\n",
       "      <th>Old CT Data</th>\n",
       "      <th>New CT Data</th>\n",
       "      <th>Old CT Data</th>\n",
       "      <th>New CT Data</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT ID</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>NCT01636492</th>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>Single Oral Ascending Dose Study of Safety, To...</td>\n",
       "      <td>Single Oral Ascending Dose Study of Safety, To...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>...</td>\n",
       "      <td>2006-08</td>\n",
       "      <td>2006-08</td>\n",
       "      <td>2012-07-10</td>\n",
       "      <td>2012-07-10</td>\n",
       "      <td>2016-11-02</td>\n",
       "      <td>2016-11-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05308472</th>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>(AURORA) A Randomized, Double-blind, Placebo-C...</td>\n",
       "      <td>(AURORA) A Randomized, Double-blind, Placebo-C...</td>\n",
       "      <td>Disc Medicine, Inc</td>\n",
       "      <td>Disc Medicine, Inc</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>...</td>\n",
       "      <td>2024-02-20</td>\n",
       "      <td>2024-02-20</td>\n",
       "      <td>2022-04-04</td>\n",
       "      <td>2022-04-04</td>\n",
       "      <td>2024-04-15</td>\n",
       "      <td>2024-04-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT01192880</th>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>A Phase III, Multi-Center, Randomized, 24 Week...</td>\n",
       "      <td>A Phase III, Multi-Center, Randomized, 24 Week...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>...</td>\n",
       "      <td>2014-07</td>\n",
       "      <td>2014-07</td>\n",
       "      <td>2010-09-01</td>\n",
       "      <td>2010-09-01</td>\n",
       "      <td>2017-02-15</td>\n",
       "      <td>2017-02-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05883748</th>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>An Open-Label, Long-Term Study to Investigate ...</td>\n",
       "      <td>An Open-Label, Long-Term Study to Investigate ...</td>\n",
       "      <td>Disc Medicine, Inc</td>\n",
       "      <td>Disc Medicine, Inc</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ENROLLING_BY_INVITATION</td>\n",
       "      <td>ENROLLING_BY_INVITATION</td>\n",
       "      <td>...</td>\n",
       "      <td>2028-06</td>\n",
       "      <td>2028-06</td>\n",
       "      <td>2023-06-01</td>\n",
       "      <td>2023-06-01</td>\n",
       "      <td>2024-02-22</td>\n",
       "      <td>2024-02-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2, PHASE3</td>\n",
       "      <td>PHASE2, PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT02019290</th>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>A SINGLE CENTER, OPEN LABEL, FIXED SEQUENCE ST...</td>\n",
       "      <td>A SINGLE CENTER, OPEN LABEL, FIXED SEQUENCE ST...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>WITHDRAWN</td>\n",
       "      <td>WITHDRAWN</td>\n",
       "      <td>...</td>\n",
       "      <td>2014-03-31</td>\n",
       "      <td>2014-03-31</td>\n",
       "      <td>2013-12-24</td>\n",
       "      <td>2013-12-24</td>\n",
       "      <td>2017-10-25</td>\n",
       "      <td>2017-10-25</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06297603</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Retatrutide</td>\n",
       "      <td>NaN</td>\n",
       "      <td>A Phase 3, Randomized, Multicenter, Double-Bli...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>NaN</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2026-09-11</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2024-03-07</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2024-06-20</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>NaN</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06383390</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Retatrutide</td>\n",
       "      <td>NaN</td>\n",
       "      <td>A Phase 3, Randomized, Double-Blind, Placebo-C...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>NaN</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2029-02</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2024-04-25</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2024-06-26</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>NaN</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05929079</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Retatrutide</td>\n",
       "      <td>NaN</td>\n",
       "      <td>A Master Protocol to Investigate the Efficacy ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TRIUMPH-2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2026-05-03</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2023-07-03</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2024-06-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>NaN</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05882045</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Retatrutide</td>\n",
       "      <td>NaN</td>\n",
       "      <td>A Randomized, Double-Blind, Phase 3 Study to I...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TRIUMPH-3</td>\n",
       "      <td>NaN</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2026-01-20</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2023-05-31</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2024-06-21</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>NaN</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05936151</th>\n",
       "      <td>NaN</td>\n",
       "      <td>Retatrutide</td>\n",
       "      <td>NaN</td>\n",
       "      <td>A Phase 2b, Double-Blind Study to Investigate ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>NaN</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2025-11-25</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2023-07-07</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2024-06-24</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>NaN</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>66 rows Ã— 34 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                  Asset               \\\n",
       "            Old CT Data  New CT Data   \n",
       "NCT ID                                 \n",
       "NCT01636492  Bitopertin   Bitopertin   \n",
       "NCT05308472  Bitopertin   Bitopertin   \n",
       "NCT01192880  Bitopertin   Bitopertin   \n",
       "NCT05883748  Bitopertin   Bitopertin   \n",
       "NCT02019290  Bitopertin   Bitopertin   \n",
       "...                 ...          ...   \n",
       "NCT06297603         NaN  Retatrutide   \n",
       "NCT06383390         NaN  Retatrutide   \n",
       "NCT05929079         NaN  Retatrutide   \n",
       "NCT05882045         NaN  Retatrutide   \n",
       "NCT05936151         NaN  Retatrutide   \n",
       "\n",
       "                                                         Title  \\\n",
       "                                                   Old CT Data   \n",
       "NCT ID                                                           \n",
       "NCT01636492  Single Oral Ascending Dose Study of Safety, To...   \n",
       "NCT05308472  (AURORA) A Randomized, Double-blind, Placebo-C...   \n",
       "NCT01192880  A Phase III, Multi-Center, Randomized, 24 Week...   \n",
       "NCT05883748  An Open-Label, Long-Term Study to Investigate ...   \n",
       "NCT02019290  A SINGLE CENTER, OPEN LABEL, FIXED SEQUENCE ST...   \n",
       "...                                                        ...   \n",
       "NCT06297603                                                NaN   \n",
       "NCT06383390                                                NaN   \n",
       "NCT05929079                                                NaN   \n",
       "NCT05882045                                                NaN   \n",
       "NCT05936151                                                NaN   \n",
       "\n",
       "                                                                \\\n",
       "                                                   New CT Data   \n",
       "NCT ID                                                           \n",
       "NCT01636492  Single Oral Ascending Dose Study of Safety, To...   \n",
       "NCT05308472  (AURORA) A Randomized, Double-blind, Placebo-C...   \n",
       "NCT01192880  A Phase III, Multi-Center, Randomized, 24 Week...   \n",
       "NCT05883748  An Open-Label, Long-Term Study to Investigate ...   \n",
       "NCT02019290  A SINGLE CENTER, OPEN LABEL, FIXED SEQUENCE ST...   \n",
       "...                                                        ...   \n",
       "NCT06297603  A Phase 3, Randomized, Multicenter, Double-Bli...   \n",
       "NCT06383390  A Phase 3, Randomized, Double-Blind, Placebo-C...   \n",
       "NCT05929079  A Master Protocol to Investigate the Efficacy ...   \n",
       "NCT05882045  A Randomized, Double-Blind, Phase 3 Study to I...   \n",
       "NCT05936151  A Phase 2b, Double-Blind Study to Investigate ...   \n",
       "\n",
       "                   Lead Sponsor                            Acronym  \\\n",
       "                    Old CT Data            New CT Data Old CT Data   \n",
       "NCT ID                                                               \n",
       "NCT01636492   Hoffmann-La Roche      Hoffmann-La Roche     Unknown   \n",
       "NCT05308472  Disc Medicine, Inc     Disc Medicine, Inc     Unknown   \n",
       "NCT01192880   Hoffmann-La Roche      Hoffmann-La Roche     Unknown   \n",
       "NCT05883748  Disc Medicine, Inc     Disc Medicine, Inc     Unknown   \n",
       "NCT02019290   Hoffmann-La Roche      Hoffmann-La Roche     Unknown   \n",
       "...                         ...                    ...         ...   \n",
       "NCT06297603                 NaN  Eli Lilly and Company         NaN   \n",
       "NCT06383390                 NaN  Eli Lilly and Company         NaN   \n",
       "NCT05929079                 NaN  Eli Lilly and Company         NaN   \n",
       "NCT05882045                 NaN  Eli Lilly and Company         NaN   \n",
       "NCT05936151                 NaN  Eli Lilly and Company         NaN   \n",
       "\n",
       "                                  Overall Status                           \\\n",
       "            New CT Data              Old CT Data              New CT Data   \n",
       "NCT ID                                                                      \n",
       "NCT01636492     Unknown                COMPLETED                COMPLETED   \n",
       "NCT05308472     Unknown    ACTIVE_NOT_RECRUITING    ACTIVE_NOT_RECRUITING   \n",
       "NCT01192880     Unknown                COMPLETED                COMPLETED   \n",
       "NCT05883748     Unknown  ENROLLING_BY_INVITATION  ENROLLING_BY_INVITATION   \n",
       "NCT02019290     Unknown                WITHDRAWN                WITHDRAWN   \n",
       "...                 ...                      ...                      ...   \n",
       "NCT06297603     Unknown                      NaN               RECRUITING   \n",
       "NCT06383390     Unknown                      NaN               RECRUITING   \n",
       "NCT05929079   TRIUMPH-2                      NaN               RECRUITING   \n",
       "NCT05882045   TRIUMPH-3                      NaN               RECRUITING   \n",
       "NCT05936151     Unknown                      NaN               RECRUITING   \n",
       "\n",
       "             ... Primary Completion Date             Study First Post Date  \\\n",
       "             ...             Old CT Data New CT Data           Old CT Data   \n",
       "NCT ID       ...                                                             \n",
       "NCT01636492  ...                 2006-08     2006-08            2012-07-10   \n",
       "NCT05308472  ...              2024-02-20  2024-02-20            2022-04-04   \n",
       "NCT01192880  ...                 2014-07     2014-07            2010-09-01   \n",
       "NCT05883748  ...                 2028-06     2028-06            2023-06-01   \n",
       "NCT02019290  ...              2014-03-31  2014-03-31            2013-12-24   \n",
       "...          ...                     ...         ...                   ...   \n",
       "NCT06297603  ...                     NaN  2026-09-11                   NaN   \n",
       "NCT06383390  ...                     NaN     2029-02                   NaN   \n",
       "NCT05929079  ...                     NaN  2026-05-03                   NaN   \n",
       "NCT05882045  ...                     NaN  2026-01-20                   NaN   \n",
       "NCT05936151  ...                     NaN  2025-11-25                   NaN   \n",
       "\n",
       "                        Last Update Post Date                  Study Type  \\\n",
       "            New CT Data           Old CT Data New CT Data     Old CT Data   \n",
       "NCT ID                                                                      \n",
       "NCT01636492  2012-07-10            2016-11-02  2016-11-02  INTERVENTIONAL   \n",
       "NCT05308472  2022-04-04            2024-04-15  2024-04-15  INTERVENTIONAL   \n",
       "NCT01192880  2010-09-01            2017-02-15  2017-02-15  INTERVENTIONAL   \n",
       "NCT05883748  2023-06-01            2024-02-22  2024-02-22  INTERVENTIONAL   \n",
       "NCT02019290  2013-12-24            2017-10-25  2017-10-25  INTERVENTIONAL   \n",
       "...                 ...                   ...         ...             ...   \n",
       "NCT06297603  2024-03-07                   NaN  2024-06-20             NaN   \n",
       "NCT06383390  2024-04-25                   NaN  2024-06-26             NaN   \n",
       "NCT05929079  2023-07-03                   NaN  2024-06-18             NaN   \n",
       "NCT05882045  2023-05-31                   NaN  2024-06-21             NaN   \n",
       "NCT05936151  2023-07-07                   NaN  2024-06-24             NaN   \n",
       "\n",
       "                                     Phases                  \n",
       "                New CT Data     Old CT Data     New CT Data  \n",
       "NCT ID                                                       \n",
       "NCT01636492  INTERVENTIONAL          PHASE1          PHASE1  \n",
       "NCT05308472  INTERVENTIONAL          PHASE2          PHASE2  \n",
       "NCT01192880  INTERVENTIONAL          PHASE3          PHASE3  \n",
       "NCT05883748  INTERVENTIONAL  PHASE2, PHASE3  PHASE2, PHASE3  \n",
       "NCT02019290  INTERVENTIONAL          PHASE1          PHASE1  \n",
       "...                     ...             ...             ...  \n",
       "NCT06297603  INTERVENTIONAL             NaN          PHASE3  \n",
       "NCT06383390  INTERVENTIONAL             NaN          PHASE3  \n",
       "NCT05929079  INTERVENTIONAL             NaN          PHASE3  \n",
       "NCT05882045  INTERVENTIONAL             NaN          PHASE3  \n",
       "NCT05936151  INTERVENTIONAL             NaN          PHASE2  \n",
       "\n",
       "[66 rows x 34 columns]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Added rows:\n",
      "\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Asset</th>\n",
       "      <th>Title</th>\n",
       "      <th>Lead Sponsor</th>\n",
       "      <th>Acronym</th>\n",
       "      <th>Overall Status</th>\n",
       "      <th>Enrollment</th>\n",
       "      <th>Start Date</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Primary Outcome(s)</th>\n",
       "      <th>Secondary Outcome(s)</th>\n",
       "      <th>Locations</th>\n",
       "      <th>Primary Completion Date</th>\n",
       "      <th>Study First Post Date</th>\n",
       "      <th>Last Update Post Date</th>\n",
       "      <th>Study Type</th>\n",
       "      <th>Phases</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT ID</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>NCT05929066</th>\n",
       "      <td>Retatrutide</td>\n",
       "      <td>A Master Protocol to Investigate the Efficacy ...</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>TRIUMPH-1</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>2100</td>\n",
       "      <td>2023-07-10</td>\n",
       "      <td>Obesity, Overweight, Knee Pain Chronic, Knee O...</td>\n",
       "      <td>Retatrutide, Placebo</td>\n",
       "      <td>Percent Change From Baseline in Body Weight, C...</td>\n",
       "      <td>Change from Baseline in Body Mass Index (BMI),...</td>\n",
       "      <td>Phoenix - United States, Phoenix - United Stat...</td>\n",
       "      <td>2026-04-15</td>\n",
       "      <td>2023-07-03</td>\n",
       "      <td>2024-06-18</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06354660</th>\n",
       "      <td>Retatrutide</td>\n",
       "      <td>A Phase 3, Randomized, Multicenter, Double-Bli...</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>480</td>\n",
       "      <td>2024-04-10</td>\n",
       "      <td>Diabetes Type 2</td>\n",
       "      <td>Retatrutide, Placebo</td>\n",
       "      <td>Change from Baseline in Hemoglobin A1c (HbA1c)...</td>\n",
       "      <td>Percentage of Participants Who Achieve HbA1c &lt;...</td>\n",
       "      <td>Scottsdale - United States, Tucson - United St...</td>\n",
       "      <td>2026-06</td>\n",
       "      <td>2024-04-09</td>\n",
       "      <td>2024-05-28</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06260722</th>\n",
       "      <td>Retatrutide</td>\n",
       "      <td>A Phase 3, Randomized, Multicenter, Open-label...</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>1250</td>\n",
       "      <td>2024-02-21</td>\n",
       "      <td>Diabetes Mellitus, Type 2</td>\n",
       "      <td>Retatrutide, Semaglutide</td>\n",
       "      <td>Change from Baseline in Hemoglobin A1c (HbA1c)...</td>\n",
       "      <td>Change from Baseline in HbA1c (%), Percentage ...</td>\n",
       "      <td>Birmingham - United States, Escondido - United...</td>\n",
       "      <td>2026-12-11</td>\n",
       "      <td>2024-02-15</td>\n",
       "      <td>2024-06-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05931367</th>\n",
       "      <td>Retatrutide</td>\n",
       "      <td>A Phase 3 Study to Investigate the Efficacy an...</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>TRIUMPH-4</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>405</td>\n",
       "      <td>2023-08-01</td>\n",
       "      <td>Obesity, Overweight, Osteo Arthritis Knee</td>\n",
       "      <td>Retatrutide, Placebo</td>\n",
       "      <td>Change from Baseline in the Western Ontario an...</td>\n",
       "      <td>Change from Baseline in the WOMAC Physical Fun...</td>\n",
       "      <td>Phoenix - United States, San Diego - United St...</td>\n",
       "      <td>2026-02-06</td>\n",
       "      <td>2023-07-05</td>\n",
       "      <td>2024-06-18</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06297603</th>\n",
       "      <td>Retatrutide</td>\n",
       "      <td>A Phase 3, Randomized, Multicenter, Double-Bli...</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>320</td>\n",
       "      <td>2024-03-15</td>\n",
       "      <td>Type 2 Diabetes</td>\n",
       "      <td>Retatrutide, Placebo</td>\n",
       "      <td>Change from Baseline in Hemoglobin A1c (HbA1c)...</td>\n",
       "      <td>Percentage of Participants Achieving HbA1c &lt;7....</td>\n",
       "      <td>Sun City West - United States, La Mesa - Unite...</td>\n",
       "      <td>2026-09-11</td>\n",
       "      <td>2024-03-07</td>\n",
       "      <td>2024-06-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06383390</th>\n",
       "      <td>Retatrutide</td>\n",
       "      <td>A Phase 3, Randomized, Double-Blind, Placebo-C...</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>10000</td>\n",
       "      <td>2024-04-30</td>\n",
       "      <td>Overweight and Obesity</td>\n",
       "      <td>Retatrutide, Placebo</td>\n",
       "      <td>Time to First Occurrence of Composite Endpoint...</td>\n",
       "      <td>Time to First Occurrence of Composite Endpoint...</td>\n",
       "      <td>Birmingham - United States, Daphne - United St...</td>\n",
       "      <td>2029-02</td>\n",
       "      <td>2024-04-25</td>\n",
       "      <td>2024-06-26</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05929079</th>\n",
       "      <td>Retatrutide</td>\n",
       "      <td>A Master Protocol to Investigate the Efficacy ...</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>TRIUMPH-2</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>1000</td>\n",
       "      <td>2023-07-11</td>\n",
       "      <td>Type 2 Diabetes, Obesity, Overweight, Obstruct...</td>\n",
       "      <td>Retatrutide, Placebo</td>\n",
       "      <td>Percent Change from Baseline in Body Weight, C...</td>\n",
       "      <td>Change from Baseline in Body Mass Index (BMI),...</td>\n",
       "      <td>Anniston - United States, Cullman - United Sta...</td>\n",
       "      <td>2026-05-03</td>\n",
       "      <td>2023-07-03</td>\n",
       "      <td>2024-06-18</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05882045</th>\n",
       "      <td>Retatrutide</td>\n",
       "      <td>A Randomized, Double-Blind, Phase 3 Study to I...</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>TRIUMPH-3</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>1800</td>\n",
       "      <td>2023-05-30</td>\n",
       "      <td>Obesity, Cardiovascular Diseases</td>\n",
       "      <td>Retatrutide, Placebo</td>\n",
       "      <td>Percent Change from Baseline in Body Weight</td>\n",
       "      <td>Change from Baseline in Body Mass Index (BMI),...</td>\n",
       "      <td>Phoenix - United States, Covina - United State...</td>\n",
       "      <td>2026-01-20</td>\n",
       "      <td>2023-05-31</td>\n",
       "      <td>2024-06-21</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05936151</th>\n",
       "      <td>Retatrutide</td>\n",
       "      <td>A Phase 2b, Double-Blind Study to Investigate ...</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>120</td>\n",
       "      <td>2023-07-20</td>\n",
       "      <td>Overweight or Obesity, CKD, Type 2 Diabetes</td>\n",
       "      <td>LY3437943, Placebo</td>\n",
       "      <td>Change from Baseline in Glomerular Filtration ...</td>\n",
       "      <td>Change from Baseline in Urine Albumin-to-Creat...</td>\n",
       "      <td>Mesa - United States, Scottsdale - United Stat...</td>\n",
       "      <td>2025-11-25</td>\n",
       "      <td>2023-07-07</td>\n",
       "      <td>2024-06-24</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                   Asset                                              Title  \\\n",
       "NCT ID                                                                        \n",
       "NCT05929066  Retatrutide  A Master Protocol to Investigate the Efficacy ...   \n",
       "NCT06354660  Retatrutide  A Phase 3, Randomized, Multicenter, Double-Bli...   \n",
       "NCT06260722  Retatrutide  A Phase 3, Randomized, Multicenter, Open-label...   \n",
       "NCT05931367  Retatrutide  A Phase 3 Study to Investigate the Efficacy an...   \n",
       "NCT06297603  Retatrutide  A Phase 3, Randomized, Multicenter, Double-Bli...   \n",
       "NCT06383390  Retatrutide  A Phase 3, Randomized, Double-Blind, Placebo-C...   \n",
       "NCT05929079  Retatrutide  A Master Protocol to Investigate the Efficacy ...   \n",
       "NCT05882045  Retatrutide  A Randomized, Double-Blind, Phase 3 Study to I...   \n",
       "NCT05936151  Retatrutide  A Phase 2b, Double-Blind Study to Investigate ...   \n",
       "\n",
       "                      Lead Sponsor    Acronym Overall Status Enrollment  \\\n",
       "NCT ID                                                                    \n",
       "NCT05929066  Eli Lilly and Company  TRIUMPH-1     RECRUITING       2100   \n",
       "NCT06354660  Eli Lilly and Company    Unknown     RECRUITING        480   \n",
       "NCT06260722  Eli Lilly and Company    Unknown     RECRUITING       1250   \n",
       "NCT05931367  Eli Lilly and Company  TRIUMPH-4     RECRUITING        405   \n",
       "NCT06297603  Eli Lilly and Company    Unknown     RECRUITING        320   \n",
       "NCT06383390  Eli Lilly and Company    Unknown     RECRUITING      10000   \n",
       "NCT05929079  Eli Lilly and Company  TRIUMPH-2     RECRUITING       1000   \n",
       "NCT05882045  Eli Lilly and Company  TRIUMPH-3     RECRUITING       1800   \n",
       "NCT05936151  Eli Lilly and Company    Unknown     RECRUITING        120   \n",
       "\n",
       "             Start Date                                         Conditions  \\\n",
       "NCT ID                                                                       \n",
       "NCT05929066  2023-07-10  Obesity, Overweight, Knee Pain Chronic, Knee O...   \n",
       "NCT06354660  2024-04-10                                    Diabetes Type 2   \n",
       "NCT06260722  2024-02-21                          Diabetes Mellitus, Type 2   \n",
       "NCT05931367  2023-08-01          Obesity, Overweight, Osteo Arthritis Knee   \n",
       "NCT06297603  2024-03-15                                    Type 2 Diabetes   \n",
       "NCT06383390  2024-04-30                             Overweight and Obesity   \n",
       "NCT05929079  2023-07-11  Type 2 Diabetes, Obesity, Overweight, Obstruct...   \n",
       "NCT05882045  2023-05-30                   Obesity, Cardiovascular Diseases   \n",
       "NCT05936151  2023-07-20        Overweight or Obesity, CKD, Type 2 Diabetes   \n",
       "\n",
       "                        Interventions  \\\n",
       "NCT ID                                  \n",
       "NCT05929066      Retatrutide, Placebo   \n",
       "NCT06354660      Retatrutide, Placebo   \n",
       "NCT06260722  Retatrutide, Semaglutide   \n",
       "NCT05931367      Retatrutide, Placebo   \n",
       "NCT06297603      Retatrutide, Placebo   \n",
       "NCT06383390      Retatrutide, Placebo   \n",
       "NCT05929079      Retatrutide, Placebo   \n",
       "NCT05882045      Retatrutide, Placebo   \n",
       "NCT05936151        LY3437943, Placebo   \n",
       "\n",
       "                                            Primary Outcome(s)  \\\n",
       "NCT ID                                                           \n",
       "NCT05929066  Percent Change From Baseline in Body Weight, C...   \n",
       "NCT06354660  Change from Baseline in Hemoglobin A1c (HbA1c)...   \n",
       "NCT06260722  Change from Baseline in Hemoglobin A1c (HbA1c)...   \n",
       "NCT05931367  Change from Baseline in the Western Ontario an...   \n",
       "NCT06297603  Change from Baseline in Hemoglobin A1c (HbA1c)...   \n",
       "NCT06383390  Time to First Occurrence of Composite Endpoint...   \n",
       "NCT05929079  Percent Change from Baseline in Body Weight, C...   \n",
       "NCT05882045        Percent Change from Baseline in Body Weight   \n",
       "NCT05936151  Change from Baseline in Glomerular Filtration ...   \n",
       "\n",
       "                                          Secondary Outcome(s)  \\\n",
       "NCT ID                                                           \n",
       "NCT05929066  Change from Baseline in Body Mass Index (BMI),...   \n",
       "NCT06354660  Percentage of Participants Who Achieve HbA1c <...   \n",
       "NCT06260722  Change from Baseline in HbA1c (%), Percentage ...   \n",
       "NCT05931367  Change from Baseline in the WOMAC Physical Fun...   \n",
       "NCT06297603  Percentage of Participants Achieving HbA1c <7....   \n",
       "NCT06383390  Time to First Occurrence of Composite Endpoint...   \n",
       "NCT05929079  Change from Baseline in Body Mass Index (BMI),...   \n",
       "NCT05882045  Change from Baseline in Body Mass Index (BMI),...   \n",
       "NCT05936151  Change from Baseline in Urine Albumin-to-Creat...   \n",
       "\n",
       "                                                     Locations  \\\n",
       "NCT ID                                                           \n",
       "NCT05929066  Phoenix - United States, Phoenix - United Stat...   \n",
       "NCT06354660  Scottsdale - United States, Tucson - United St...   \n",
       "NCT06260722  Birmingham - United States, Escondido - United...   \n",
       "NCT05931367  Phoenix - United States, San Diego - United St...   \n",
       "NCT06297603  Sun City West - United States, La Mesa - Unite...   \n",
       "NCT06383390  Birmingham - United States, Daphne - United St...   \n",
       "NCT05929079  Anniston - United States, Cullman - United Sta...   \n",
       "NCT05882045  Phoenix - United States, Covina - United State...   \n",
       "NCT05936151  Mesa - United States, Scottsdale - United Stat...   \n",
       "\n",
       "            Primary Completion Date Study First Post Date  \\\n",
       "NCT ID                                                      \n",
       "NCT05929066              2026-04-15            2023-07-03   \n",
       "NCT06354660                 2026-06            2024-04-09   \n",
       "NCT06260722              2026-12-11            2024-02-15   \n",
       "NCT05931367              2026-02-06            2023-07-05   \n",
       "NCT06297603              2026-09-11            2024-03-07   \n",
       "NCT06383390                 2029-02            2024-04-25   \n",
       "NCT05929079              2026-05-03            2023-07-03   \n",
       "NCT05882045              2026-01-20            2023-05-31   \n",
       "NCT05936151              2025-11-25            2023-07-07   \n",
       "\n",
       "            Last Update Post Date      Study Type  Phases  \n",
       "NCT ID                                                     \n",
       "NCT05929066            2024-06-18  INTERVENTIONAL  PHASE3  \n",
       "NCT06354660            2024-05-28  INTERVENTIONAL  PHASE3  \n",
       "NCT06260722            2024-06-20  INTERVENTIONAL  PHASE3  \n",
       "NCT05931367            2024-06-18  INTERVENTIONAL  PHASE3  \n",
       "NCT06297603            2024-06-20  INTERVENTIONAL  PHASE3  \n",
       "NCT06383390            2024-06-26  INTERVENTIONAL  PHASE3  \n",
       "NCT05929079            2024-06-18  INTERVENTIONAL  PHASE3  \n",
       "NCT05882045            2024-06-21  INTERVENTIONAL  PHASE3  \n",
       "NCT05936151            2024-06-24  INTERVENTIONAL  PHASE2  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Deleted rows:\n",
      "\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Asset</th>\n",
       "      <th>Title</th>\n",
       "      <th>Lead Sponsor</th>\n",
       "      <th>Acronym</th>\n",
       "      <th>Overall Status</th>\n",
       "      <th>Enrollment</th>\n",
       "      <th>Start Date</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Primary Outcome(s)</th>\n",
       "      <th>Secondary Outcome(s)</th>\n",
       "      <th>Locations</th>\n",
       "      <th>Primary Completion Date</th>\n",
       "      <th>Study First Post Date</th>\n",
       "      <th>Last Update Post Date</th>\n",
       "      <th>Study Type</th>\n",
       "      <th>Phases</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT ID</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "Empty DataFrame\n",
       "Columns: [Asset, Title, Lead Sponsor, Acronym, Overall Status, Enrollment, Start Date, Conditions, Interventions, Primary Outcome(s), Secondary Outcome(s), Locations, Primary Completion Date, Study First Post Date, Last Update Post Date, Study Type, Phases]\n",
       "Index: []"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Modified rows:\n",
      "\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Asset</th>\n",
       "      <th>Title</th>\n",
       "      <th>Lead Sponsor</th>\n",
       "      <th>Acronym</th>\n",
       "      <th>Overall Status</th>\n",
       "      <th>Enrollment</th>\n",
       "      <th>Start Date</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Primary Outcome(s)</th>\n",
       "      <th>Secondary Outcome(s)</th>\n",
       "      <th>Locations</th>\n",
       "      <th>Primary Completion Date</th>\n",
       "      <th>Study First Post Date</th>\n",
       "      <th>Last Update Post Date</th>\n",
       "      <th>Study Type</th>\n",
       "      <th>Phases</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT ID</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>NCT01636492</th>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>Single Oral Ascending Dose Study of Safety, To...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>71</td>\n",
       "      <td>2005-11</td>\n",
       "      <td>Healthy Volunteer</td>\n",
       "      <td>bitopertin, placebo</td>\n",
       "      <td>Safety: Incidence of adverse events</td>\n",
       "      <td>Pharmacokinetics: Area under the concentration...</td>\n",
       "      <td>Christchurch - New Zealand</td>\n",
       "      <td>2006-08</td>\n",
       "      <td>2012-07-10</td>\n",
       "      <td>2016-11-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05308472</th>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>(AURORA) A Randomized, Double-blind, Placebo-C...</td>\n",
       "      <td>Disc Medicine, Inc</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>75</td>\n",
       "      <td>2022-10-31</td>\n",
       "      <td>Erythropoietic Protoporphyria</td>\n",
       "      <td>DISC-1459, DISC-1459, Placebo, DISC-1459</td>\n",
       "      <td>Percent change from baseline in whole blood me...</td>\n",
       "      <td>Total hours of sunlight exposure to skin on da...</td>\n",
       "      <td>Birmingham - United States, San Francisco - Un...</td>\n",
       "      <td>2024-02-20</td>\n",
       "      <td>2022-04-04</td>\n",
       "      <td>2024-04-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT01192880</th>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>A Phase III, Multi-Center, Randomized, 24 Week...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>625</td>\n",
       "      <td>2010-11</td>\n",
       "      <td>Schizophrenia</td>\n",
       "      <td>Placebo, Bitopertin, Antipsychotics</td>\n",
       "      <td>Mean Change From Baseline in the Positive and ...</td>\n",
       "      <td>Mean Change from Baseline in the Personal and ...</td>\n",
       "      <td>Costa Mesa - United States, Escondido - United...</td>\n",
       "      <td>2014-07</td>\n",
       "      <td>2010-09-01</td>\n",
       "      <td>2017-02-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05883748</th>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>An Open-Label, Long-Term Study to Investigate ...</td>\n",
       "      <td>Disc Medicine, Inc</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ENROLLING_BY_INVITATION</td>\n",
       "      <td>200</td>\n",
       "      <td>2023-08-31</td>\n",
       "      <td>Erythropoietic Protoporphyria</td>\n",
       "      <td>DISC-1459, DISC-1459</td>\n",
       "      <td>Incidence of treatment-emergent adverse events...</td>\n",
       "      <td>Change from baseline in daily daylight toleran...</td>\n",
       "      <td>Birmingham - United States, San Francisco - Un...</td>\n",
       "      <td>2028-06</td>\n",
       "      <td>2023-06-01</td>\n",
       "      <td>2024-02-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2, PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT02019290</th>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>A SINGLE CENTER, OPEN LABEL, FIXED SEQUENCE ST...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>WITHDRAWN</td>\n",
       "      <td>0</td>\n",
       "      <td>2014-02-10</td>\n",
       "      <td>Healthy Volunteer</td>\n",
       "      <td>Midazolam, bitopertin</td>\n",
       "      <td>Change in plasma area under the concentration-...</td>\n",
       "      <td>Change in 1'-hydroxymidazolam plasma AUC after...</td>\n",
       "      <td>No locations listed</td>\n",
       "      <td>2014-03-31</td>\n",
       "      <td>2013-12-24</td>\n",
       "      <td>2017-10-25</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05828108</th>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>A Phase I/II, Intra-Patient Dose-Escalation St...</td>\n",
       "      <td>National Heart, Lung, and Blood Institute (NHLBI)</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>30</td>\n",
       "      <td>2023-07-25</td>\n",
       "      <td>Steroid-refractory Diamond-Blackfan Anemia (DBA)</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>Rate of response</td>\n",
       "      <td>Rate of relapse, Long-term safety of drug, Tol...</td>\n",
       "      <td>Bethesda - United States</td>\n",
       "      <td>2029-05-01</td>\n",
       "      <td>2023-04-25</td>\n",
       "      <td>2024-04-10</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT03271541</th>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>A Phase II, Single Arm, Multicenter, Proof-of-...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>12</td>\n",
       "      <td>2017-10-26</td>\n",
       "      <td>Beta-Thalassemia</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>Safety Outcome: Percentage of Participants wit...</td>\n",
       "      <td>Apparent Clearance of Bitopertin, Volume of Di...</td>\n",
       "      <td>Genova - Italy, Milano - Italy, Baabda - Leban...</td>\n",
       "      <td>2018-06-29</td>\n",
       "      <td>2017-09-05</td>\n",
       "      <td>2018-10-05</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT01192906</th>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>A Phase III, Multi-center, Randomized, 24 Week...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>624</td>\n",
       "      <td>2010-12</td>\n",
       "      <td>Schizophrenia</td>\n",
       "      <td>Placebo, bitopertin [RO4917838], bitopertin [R...</td>\n",
       "      <td>Efficacy (PANSS negative symptoms factor score...</td>\n",
       "      <td>No secondary outcomes listed</td>\n",
       "      <td>Carson - United States, Oceanside - United Sta...</td>\n",
       "      <td>2014-07</td>\n",
       "      <td>2010-09-01</td>\n",
       "      <td>2016-11-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT01234779</th>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>A Phase II, Multi-center, Randomized, 4-week, ...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>301</td>\n",
       "      <td>2011-02</td>\n",
       "      <td>Schizophrenia</td>\n",
       "      <td>bitopertin [RO4917838], bitopertin [RO4917838]...</td>\n",
       "      <td>Change in Positive and Negative Syndrome Scale...</td>\n",
       "      <td>Clinical response, defined as at least 30% or ...</td>\n",
       "      <td>Little Rock - United States, Cerritos - United...</td>\n",
       "      <td>2012-09</td>\n",
       "      <td>2010-11-04</td>\n",
       "      <td>2016-11-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT01235559</th>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>Phase III, Multi-center, Randomized, 12-week, ...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>604</td>\n",
       "      <td>2010-12</td>\n",
       "      <td>Schizophrenia</td>\n",
       "      <td>Placebo, bitopertin [RO4917838] level 1, bitop...</td>\n",
       "      <td>Positive symptoms factor score assessed by Pos...</td>\n",
       "      <td>Symptom domains of schizophrenia using Positiv...</td>\n",
       "      <td>Costa Mesa - United States, Escondido - United...</td>\n",
       "      <td>2015-03</td>\n",
       "      <td>2010-11-05</td>\n",
       "      <td>2016-11-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT01235585</th>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>Phase III, Multi-center, Randomized, 12-week, ...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>597</td>\n",
       "      <td>2010-12</td>\n",
       "      <td>Schizophrenia</td>\n",
       "      <td>Placebo, bitopertin [RO4917838], bitopertin [R...</td>\n",
       "      <td>Positive symptoms factor score assessed by Pos...</td>\n",
       "      <td>Symptom domains of schizophrenia using Positiv...</td>\n",
       "      <td>Carson - United States, Garden Grove - United ...</td>\n",
       "      <td>2014-09</td>\n",
       "      <td>2010-11-05</td>\n",
       "      <td>2016-11-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT01674361</th>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>A Phase II, Multicenter, Randomized, Double-Bl...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>99</td>\n",
       "      <td>2012-12-31</td>\n",
       "      <td>Obsessive-Compulsive Disorder</td>\n",
       "      <td>Bitopertin, Placebo, SSRI</td>\n",
       "      <td>Change From Baseline in Total Score on Yale-Br...</td>\n",
       "      <td>Change From Baseline in Clinical Global Impres...</td>\n",
       "      <td>Oceanside - United States, Stanford - United S...</td>\n",
       "      <td>2015-04-30</td>\n",
       "      <td>2012-08-28</td>\n",
       "      <td>2017-08-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06139055</th>\n",
       "      <td>GSBR-1290</td>\n",
       "      <td>A 2-part, Phase 1, Randomized Study to Evaluat...</td>\n",
       "      <td>Gasherbrum Bio, Inc</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>70</td>\n",
       "      <td>2023-10-02</td>\n",
       "      <td>Healthy Volunteers</td>\n",
       "      <td>GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo...</td>\n",
       "      <td>Part 1: Analysis of Maximum Observed Plasma Co...</td>\n",
       "      <td>Part 1: Number of Participants With Adverse Ev...</td>\n",
       "      <td>Miami - United States, Miami - United States, ...</td>\n",
       "      <td>2024-03</td>\n",
       "      <td>2023-11-18</td>\n",
       "      <td>2024-02-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05893043</th>\n",
       "      <td>GSBR-1290</td>\n",
       "      <td>A Phase 1, Randomized, Double-blind, Placebo-c...</td>\n",
       "      <td>Gasherbrum Bio, Inc</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>18</td>\n",
       "      <td>2023-04-24</td>\n",
       "      <td>Healthy Volunteers</td>\n",
       "      <td>GSBR-1290, Placebo</td>\n",
       "      <td>Number of Participants With Adverse Events (AE...</td>\n",
       "      <td>Analysis of Maximum Observed Plasma Concentrat...</td>\n",
       "      <td>Anaheim - United States</td>\n",
       "      <td>2023-06-28</td>\n",
       "      <td>2023-06-07</td>\n",
       "      <td>2023-07-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05762471</th>\n",
       "      <td>GSBR-1290</td>\n",
       "      <td>A Phase 1b/2a, Randomized, Double-blind, Place...</td>\n",
       "      <td>Gasherbrum Bio, Inc</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>142</td>\n",
       "      <td>2023-01-09</td>\n",
       "      <td>Overweight or Obesity, Type2 Diabetes Mellitus</td>\n",
       "      <td>GSBR-1290, Placebo</td>\n",
       "      <td>Incidence, severity and relationship of AE/SAE...</td>\n",
       "      <td>Analysis of Cmax at specified timepoints predo...</td>\n",
       "      <td>Anaheim - United States, Chula Vista - United ...</td>\n",
       "      <td>2024-04-11</td>\n",
       "      <td>2023-03-09</td>\n",
       "      <td>2024-04-25</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT02709876</th>\n",
       "      <td>RP-1</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Stem Cells Arabia</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>50</td>\n",
       "      <td>2014-04</td>\n",
       "      <td>Retinitis Pigmentosa</td>\n",
       "      <td>Stem Cell Transplantation</td>\n",
       "      <td>ETDRS Visual acuity change</td>\n",
       "      <td>Quality of Life: Questionnaire VFQ-25 (Visual ...</td>\n",
       "      <td>Amman - Jordan</td>\n",
       "      <td>2020-09</td>\n",
       "      <td>2016-03-16</td>\n",
       "      <td>2020-03-17</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT04776889</th>\n",
       "      <td>RP-1</td>\n",
       "      <td>The Prognosis of Lipid Reprogramming With the ...</td>\n",
       "      <td>National Cancer Institute, Egypt</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>70</td>\n",
       "      <td>2019-01-15</td>\n",
       "      <td>Prostate Cancer Metastatic</td>\n",
       "      <td>Rosuvastatin 20mg, surgical castration</td>\n",
       "      <td>Lipid profile, Aggressiveness parameters, Aggr...</td>\n",
       "      <td>short-term clinical outcome, short-term clinic...</td>\n",
       "      <td>Cairo - Egypt</td>\n",
       "      <td>2020-12-30</td>\n",
       "      <td>2021-03-02</td>\n",
       "      <td>2021-03-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06264180</th>\n",
       "      <td>RP-1</td>\n",
       "      <td>Randomized, Ph3 Clinical Study Comparing Vusol...</td>\n",
       "      <td>Replimune Inc.</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>NOT_YET_RECRUITING</td>\n",
       "      <td>400</td>\n",
       "      <td>2024-06-01</td>\n",
       "      <td>Advanced Melanoma</td>\n",
       "      <td>Vusolimogene Oderparepvec, Nivolumab, Nivoluma...</td>\n",
       "      <td>Overall Survival (OS)</td>\n",
       "      <td>Progression Free Survival (PFS), Objective Res...</td>\n",
       "      <td>No locations listed</td>\n",
       "      <td>2029-01-01</td>\n",
       "      <td>2024-02-16</td>\n",
       "      <td>2024-02-16</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05858229</th>\n",
       "      <td>RP-1</td>\n",
       "      <td>A Phase 1B Study of Intralesional Injection of...</td>\n",
       "      <td>Sherrif Ibrahim</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>12</td>\n",
       "      <td>2023-06-16</td>\n",
       "      <td>Squamous Cell Carcinoma, RP1</td>\n",
       "      <td>RP1</td>\n",
       "      <td>Evaluate degree of pathologic response at 16 w...</td>\n",
       "      <td>Evaluate the duration of response, Evaluate pr...</td>\n",
       "      <td>Victor - United States</td>\n",
       "      <td>2025-12</td>\n",
       "      <td>2023-05-15</td>\n",
       "      <td>2024-03-26</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT03767348</th>\n",
       "      <td>RP-1</td>\n",
       "      <td>An Open-Label, Multicenter, Phase 1/2 Study of...</td>\n",
       "      <td>Replimune Inc.</td>\n",
       "      <td>IGNYTE</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>340</td>\n",
       "      <td>2017-09-20</td>\n",
       "      <td>Cancer, Melanoma (Skin), Mismatch Repair Defic...</td>\n",
       "      <td>RP1, nivolumab</td>\n",
       "      <td>Percentage of adverse events (AEs), Percentage...</td>\n",
       "      <td>Percentage of biologic activity, Percentage su...</td>\n",
       "      <td>Birmingham - United States, Gilbert - United S...</td>\n",
       "      <td>2024-11</td>\n",
       "      <td>2018-12-06</td>\n",
       "      <td>2023-08-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06395116</th>\n",
       "      <td>RP-1</td>\n",
       "      <td>\"Influence of Fabrication Technique on Microbi...</td>\n",
       "      <td>Menoufia University</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>60</td>\n",
       "      <td>2023-01-20</td>\n",
       "      <td>Inflammatory Response, Microbial Colonization,...</td>\n",
       "      <td>Denture base material</td>\n",
       "      <td>Biofilm formation</td>\n",
       "      <td>No secondary outcomes listed</td>\n",
       "      <td>Mansoura - Egypt</td>\n",
       "      <td>2024-07-04</td>\n",
       "      <td>2024-05-01</td>\n",
       "      <td>2024-05-01</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>Not Available</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT02786381</th>\n",
       "      <td>RP-1</td>\n",
       "      <td>Idylla Respiratory (IFV-RSV) Panel Clinical Te...</td>\n",
       "      <td>Janssen Pharmaceutica N.V., Belgium</td>\n",
       "      <td>RP1</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>213</td>\n",
       "      <td>2015-11</td>\n",
       "      <td>Respiratory Tract Infections, Influenza, Human...</td>\n",
       "      <td>No interventions listed</td>\n",
       "      <td>Product performance as measured by positive an...</td>\n",
       "      <td>No secondary outcomes listed</td>\n",
       "      <td>Pensacola - United States</td>\n",
       "      <td>2016-10</td>\n",
       "      <td>2016-06-01</td>\n",
       "      <td>2016-11-22</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>Not Available</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06216938</th>\n",
       "      <td>RP-1</td>\n",
       "      <td>Phase I Pilot Study of RP1 in Primary Melanoma...</td>\n",
       "      <td>Yana Najjar</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>25</td>\n",
       "      <td>2024-02-02</td>\n",
       "      <td>Melanoma</td>\n",
       "      <td>Vusolimogene oderparepvec (RP1)</td>\n",
       "      <td>Rate of Sentinel Lymph Node (SLN) Positivity</td>\n",
       "      <td>Incidence of all treatment-emergent adverse ev...</td>\n",
       "      <td>Pittsburgh - United States</td>\n",
       "      <td>2026-01-31</td>\n",
       "      <td>2024-01-22</td>\n",
       "      <td>2024-03-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>EARLY_PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT04349436</th>\n",
       "      <td>RP-1</td>\n",
       "      <td>An Open-Label, Multicenter, Phase 1B/2 Study o...</td>\n",
       "      <td>Replimune Inc.</td>\n",
       "      <td>ARTACUS</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>65</td>\n",
       "      <td>2020-05-15</td>\n",
       "      <td>Cutaneous Squamous Cell Carcinoma, Merkel Cell...</td>\n",
       "      <td>RP1, intra-tumoral injection, oncolytic virus</td>\n",
       "      <td>Primary Safety Outcome Measure, Primary Effica...</td>\n",
       "      <td>Duration of response (DOR) by investigator amo...</td>\n",
       "      <td>Phoenix - United States, La Jolla - United Sta...</td>\n",
       "      <td>2027-09</td>\n",
       "      <td>2020-04-16</td>\n",
       "      <td>2024-03-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT04050436</th>\n",
       "      <td>RP-1</td>\n",
       "      <td>A Randomized, Controlled, Open-Label, Phase 2 ...</td>\n",
       "      <td>Replimune Inc.</td>\n",
       "      <td>CERPASS</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>231</td>\n",
       "      <td>2019-10-08</td>\n",
       "      <td>Cutaneous Squamous Cell Carcinoma, Advanced Cu...</td>\n",
       "      <td>Cemiplimab, RP1</td>\n",
       "      <td>Objective Response Rate (ORR) according to bli...</td>\n",
       "      <td>Progression Free Survival (PFS) by blinded ind...</td>\n",
       "      <td>La Jolla - United States, Los Angeles - United...</td>\n",
       "      <td>2025-09</td>\n",
       "      <td>2019-08-08</td>\n",
       "      <td>2024-04-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT04960579</th>\n",
       "      <td>RP-1</td>\n",
       "      <td>Open-Label, Multicenter, Phase 1 Study to Asse...</td>\n",
       "      <td>Poseida Therapeutics, Inc.</td>\n",
       "      <td>MM</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>231</td>\n",
       "      <td>2022-05-05</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>P-BCMA-ALLO1 CAR-T cells, Rimiducid</td>\n",
       "      <td>Phase 1 Part 1: Assess the safety and maximum ...</td>\n",
       "      <td>The safety of P-BCMA-ALLO1, The anti-myeloma e...</td>\n",
       "      <td>San Diego - United States, San Francisco - Uni...</td>\n",
       "      <td>2027-12</td>\n",
       "      <td>2021-07-14</td>\n",
       "      <td>2024-06-21</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT03999021</th>\n",
       "      <td>RP-1</td>\n",
       "      <td>A Phase 1 Open-Label Extension Study to Assess...</td>\n",
       "      <td>Johns Hopkins University</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>30</td>\n",
       "      <td>2019-06-24</td>\n",
       "      <td>Retinitis Pigmentosa</td>\n",
       "      <td>NAC effervescent tablets</td>\n",
       "      <td>Blood Pressure (mmHg), Tolerability of N-Acety...</td>\n",
       "      <td>Change in best corrected visual acuity (BCVA),...</td>\n",
       "      <td>Baltimore - United States</td>\n",
       "      <td>2026-08</td>\n",
       "      <td>2019-06-26</td>\n",
       "      <td>2023-10-10</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT03063021</th>\n",
       "      <td>RP-1</td>\n",
       "      <td>A Phase 1 Open Label Dose Ranging Study to Ass...</td>\n",
       "      <td>Johns Hopkins University</td>\n",
       "      <td>FIGHT-RP1</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>30</td>\n",
       "      <td>2017-02-15</td>\n",
       "      <td>Retinitis Pigmentosa</td>\n",
       "      <td>N-Acetyl Cysteine (NAC)</td>\n",
       "      <td>Assessment of safety and tolerability of N-Ace...</td>\n",
       "      <td>Change from baseline aqueous and serum carbony...</td>\n",
       "      <td>Baltimore - United States</td>\n",
       "      <td>2019-02-11</td>\n",
       "      <td>2017-02-24</td>\n",
       "      <td>2022-09-19</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06067061</th>\n",
       "      <td>RP-1</td>\n",
       "      <td>\"neoBREASTIM\": A Phase 2 Study of Atezolizumab...</td>\n",
       "      <td>Institut Curie</td>\n",
       "      <td>neoBREASTIM</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>51</td>\n",
       "      <td>2024-04-05</td>\n",
       "      <td>Triple Negative Breast Neoplasms</td>\n",
       "      <td>Atezolizumab + RP1</td>\n",
       "      <td>Safety of the combination Atezolizumab plus RP...</td>\n",
       "      <td>Response rate of RCB Score &lt;= 1 at three cycle...</td>\n",
       "      <td>Paris - France</td>\n",
       "      <td>2026-04-05</td>\n",
       "      <td>2023-10-04</td>\n",
       "      <td>2024-05-30</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT04006457</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM ...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>ALLEGRO-LT</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>1051</td>\n",
       "      <td>2019-07-18</td>\n",
       "      <td>Alopecia Areata</td>\n",
       "      <td>PF-06651600, Tetanus and diphtheria toxoids an...</td>\n",
       "      <td>Number of subjects reporting treatment-emergen...</td>\n",
       "      <td>Percentage of subjects with an absolute Severi...</td>\n",
       "      <td>Birmingham - United States, Birmingham - Unite...</td>\n",
       "      <td>2024-07-08</td>\n",
       "      <td>2019-07-05</td>\n",
       "      <td>2023-12-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06163326</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSE-UP TI...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tranquillo LTE</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>400</td>\n",
       "      <td>2024-01-19</td>\n",
       "      <td>Vitiligo</td>\n",
       "      <td>Ritlecitinib, Ritlecitinib 100 mg, Placebo</td>\n",
       "      <td>Incidence of treatment-emergent adverse events...</td>\n",
       "      <td>Response based on T-VASI75 at weeks 4, 8, 12, ...</td>\n",
       "      <td>Encinitas - United States, Huntington Beach - ...</td>\n",
       "      <td>2027-01-30</td>\n",
       "      <td>2023-12-08</td>\n",
       "      <td>2024-06-26</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05879458</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A Single-center, Single-arm, Open-label Phase ...</td>\n",
       "      <td>Icahn School of Medicine at Mount Sinai</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>20</td>\n",
       "      <td>2023-05-17</td>\n",
       "      <td>CTCL, Mycosis Fungoides, Sezary Syndrome</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>Change in Modified Severity Weighted Assessmen...</td>\n",
       "      <td>Change in Modified Severity Weighted Assessmen...</td>\n",
       "      <td>New York - United States</td>\n",
       "      <td>2026-04</td>\n",
       "      <td>2023-05-30</td>\n",
       "      <td>2024-05-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05128058</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>AN OPEN LABEL, PHASE 1, TWO-ARM STUDY TO ASSES...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>16</td>\n",
       "      <td>2021-10-22</td>\n",
       "      <td>Healthy</td>\n",
       "      <td>Ritlecitinib 50 mg, Ritlecitinib 200 mg</td>\n",
       "      <td>Percent Target Occupancy for JAK3, Percent Tar...</td>\n",
       "      <td>Maximum Observed Plasma Concentration (Cmax) o...</td>\n",
       "      <td>New Haven - United States</td>\n",
       "      <td>2022-01-14</td>\n",
       "      <td>2021-11-19</td>\n",
       "      <td>2023-11-13</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05743244</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A Phase 2 Multi-Center, Randomized, Double-Bli...</td>\n",
       "      <td>National Institute of Diabetes and Digestive a...</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>78</td>\n",
       "      <td>2023-10-19</td>\n",
       "      <td>Diabetes Mellitus, Type 1</td>\n",
       "      <td>Abrocitinib 200 MG Oral Tablet, Ritlecitinib, ...</td>\n",
       "      <td>The area under the stimulated C-peptide curve ...</td>\n",
       "      <td>No secondary outcomes listed</td>\n",
       "      <td>Orange - United States, Palo Alto - United Sta...</td>\n",
       "      <td>2026-06-30</td>\n",
       "      <td>2023-02-24</td>\n",
       "      <td>2024-05-24</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05852340</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 1, RANDOMIZED, OPEN-LABEL, CROSSOVER S...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>12</td>\n",
       "      <td>2023-05-09</td>\n",
       "      <td>Healthy Volunteers, Adult, Pharmacokinetics</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>Maximum plasma concentration (Cmax), Area unde...</td>\n",
       "      <td>Number of participants reporting adverse events</td>\n",
       "      <td>Brussels - Belgium</td>\n",
       "      <td>2023-07-12</td>\n",
       "      <td>2023-05-10</td>\n",
       "      <td>2023-08-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT04655040</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 1, 2-PERIOD, FIXED-SEQUENCE, MULTIPLE-...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>12</td>\n",
       "      <td>2020-12-18</td>\n",
       "      <td>Healthy Participants</td>\n",
       "      <td>Caffeine, Ritlecitinib</td>\n",
       "      <td>Area under the plasma concentration-time profi...</td>\n",
       "      <td>Incidence of treatment-emergent adverse events...</td>\n",
       "      <td>New Haven - United States</td>\n",
       "      <td>2021-03-05</td>\n",
       "      <td>2020-12-04</td>\n",
       "      <td>2021-03-18</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06172348</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 1, OPEN-LABEL STUDY IN HEALTHY PARTICI...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>12</td>\n",
       "      <td>2024-02-01</td>\n",
       "      <td>Healthy Volunteers</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>Maximum plasma concentration (Cmax), Area unde...</td>\n",
       "      <td>Frequency of adverse events, Frequency of abno...</td>\n",
       "      <td>Brussels - Belgium</td>\n",
       "      <td>2024-03-28</td>\n",
       "      <td>2023-12-15</td>\n",
       "      <td>2024-04-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05583526</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PL...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tranquillo</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>600</td>\n",
       "      <td>2022-12-01</td>\n",
       "      <td>Stable Nonsegmental Vitiligo, Active Nonsegmen...</td>\n",
       "      <td>Ritlecitinib, Placebo</td>\n",
       "      <td>US only Co-Primary Endpoints: Response based o...</td>\n",
       "      <td>US-Only: Response based on F-VASI75 at 24, 26 ...</td>\n",
       "      <td>Birmingham - United States, Birmingham - Unite...</td>\n",
       "      <td>2025-07-28</td>\n",
       "      <td>2022-10-17</td>\n",
       "      <td>2024-06-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06373458</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A Single-Center, Two-Arm, Open-Label Phase IIA...</td>\n",
       "      <td>Icahn School of Medicine at Mount Sinai</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>30</td>\n",
       "      <td>2024-06-30</td>\n",
       "      <td>Keloid</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>Recurrence Rate, Change in Detroid Keloid Scal...</td>\n",
       "      <td>Change in Peak keloid tension, Change in Detro...</td>\n",
       "      <td>New York - United States</td>\n",
       "      <td>2026-03</td>\n",
       "      <td>2024-04-18</td>\n",
       "      <td>2024-06-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05549934</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A Pilot Study to Assess Safety and Biomarker R...</td>\n",
       "      <td>Emma Guttman</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>50</td>\n",
       "      <td>2022-12-15</td>\n",
       "      <td>Cicatricial Alopecia</td>\n",
       "      <td>PF-06651600</td>\n",
       "      <td>Number of Treatment-Emergent Adverse Events, S...</td>\n",
       "      <td>Change in Ct values of mRNA levels of CXCR3, C...</td>\n",
       "      <td>New York - United States</td>\n",
       "      <td>2024-12</td>\n",
       "      <td>2022-09-22</td>\n",
       "      <td>2023-08-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05097716</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD ...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>12</td>\n",
       "      <td>2021-11-02</td>\n",
       "      <td>Healthy Volunteers</td>\n",
       "      <td>Ritlecitinib, Tolbutamide</td>\n",
       "      <td>Maximum Plasma Concentration (Cmax) of Tolbuta...</td>\n",
       "      <td>Number of Participants With Treatment-Emergent...</td>\n",
       "      <td>New Haven - United States</td>\n",
       "      <td>2022-01-10</td>\n",
       "      <td>2021-10-28</td>\n",
       "      <td>2023-10-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05040295</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 1, RANDOMIZED, OPEN-LABEL, CROSS-OVER,...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>12</td>\n",
       "      <td>2021-09-10</td>\n",
       "      <td>Healthy Participants</td>\n",
       "      <td>ritlecitinib, ritlecitinib, ritlecitinib</td>\n",
       "      <td>Area Under the Plasma Concentration-Time Profi...</td>\n",
       "      <td>Number of Participants With Treatment-Emergent...</td>\n",
       "      <td>New Haven - United States</td>\n",
       "      <td>2021-11-19</td>\n",
       "      <td>2021-09-10</td>\n",
       "      <td>2023-08-21</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT04413617</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A 24-WEEK RANDOMIZED, DOUBLE-BLIND, PARALLEL G...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>460</td>\n",
       "      <td>2020-07-29</td>\n",
       "      <td>Rheumatoid Arthritis</td>\n",
       "      <td>PF-06650833, PF-06651600, Tofacitinib</td>\n",
       "      <td>Change From Baseline (BL) in Disease Activity ...</td>\n",
       "      <td>DAS28-CRP Remission (&lt;2.6) Rates at Week 24, N...</td>\n",
       "      <td>Pleven - Bulgaria, Plovdiv - Bulgaria, Plovdiv...</td>\n",
       "      <td>2022-02-07</td>\n",
       "      <td>2020-06-04</td>\n",
       "      <td>2023-04-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT04517864</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Allegro2a</td>\n",
       "      <td>TERMINATED</td>\n",
       "      <td>71</td>\n",
       "      <td>2020-09-15</td>\n",
       "      <td>Alopecia Areata</td>\n",
       "      <td>PF-06651600, Placebo</td>\n",
       "      <td>Change From Baseline in I-V Interwave Latency ...</td>\n",
       "      <td>Change From Baseline in I-V Interwave Latency ...</td>\n",
       "      <td>Huntington Beach - United States, Irvine - Uni...</td>\n",
       "      <td>2022-01-04</td>\n",
       "      <td>2020-08-18</td>\n",
       "      <td>2024-06-18</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT03732807</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>ALLEGRO-2b/3</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>718</td>\n",
       "      <td>2018-12-03</td>\n",
       "      <td>Alopecia Areata</td>\n",
       "      <td>PF-06651600 Induction Dose, PF-06651600 Mainte...</td>\n",
       "      <td>Percentage of Participants With an Absolute Se...</td>\n",
       "      <td>Percentage of Participants With an Absolute SA...</td>\n",
       "      <td>Birmingham - United States, Birmingham - Unite...</td>\n",
       "      <td>2020-12-31</td>\n",
       "      <td>2018-11-07</td>\n",
       "      <td>2022-02-24</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2, PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06072183</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PL...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tranquillo 2</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>1450</td>\n",
       "      <td>2023-11-08</td>\n",
       "      <td>Stable Nonsegmental Vitiligo, Active Nonsegmen...</td>\n",
       "      <td>Ritlecitinib, Ritlecitinib, Placebo</td>\n",
       "      <td>US only Co-Primary Endpoints: Response based o...</td>\n",
       "      <td>Response based on F-VASI75 at 24 and 36 weeks,...</td>\n",
       "      <td>Birmingham - United States, Birmingham - Unite...</td>\n",
       "      <td>2027-07-14</td>\n",
       "      <td>2023-10-10</td>\n",
       "      <td>2024-06-26</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05636293</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>Double Blind, Placebo-controlled Trial to Esta...</td>\n",
       "      <td>Massachusetts General Hospital</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>30</td>\n",
       "      <td>2023-03-01</td>\n",
       "      <td>Celiac Disease</td>\n",
       "      <td>Ritlecitinib, Placebo, Gluten</td>\n",
       "      <td>Change in Small Intestinal Histology based on ...</td>\n",
       "      <td>Serology, Changes in Small Intestinal Histolog...</td>\n",
       "      <td>Boston - United States</td>\n",
       "      <td>2025-08-01</td>\n",
       "      <td>2022-12-05</td>\n",
       "      <td>2024-02-28</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05650333</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>AN INTERVENTIONAL PK, PD, PHASE 1, OPEN-LABEL ...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>15</td>\n",
       "      <td>2023-03-02</td>\n",
       "      <td>Alopecia Areata</td>\n",
       "      <td>Ritlecitinib 20 mg</td>\n",
       "      <td>Area under the plasma concentration time profi...</td>\n",
       "      <td>Maximum Observed Plasma Concentration (Cmax), ...</td>\n",
       "      <td>Encinitas - United States, Coral Gables - Unit...</td>\n",
       "      <td>2023-08-11</td>\n",
       "      <td>2022-12-14</td>\n",
       "      <td>2023-08-25</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06369454</th>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 1, RANDOMIZED, OPEN-LABEL, 2-SEQUENCE,...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>6</td>\n",
       "      <td>2024-05-03</td>\n",
       "      <td>Healthy Volunteers</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>Site of capsule disintegration and MR microsph...</td>\n",
       "      <td>Maximum plasma concentration (Cmax), Area unde...</td>\n",
       "      <td>Lexington - United States</td>\n",
       "      <td>2024-08-02</td>\n",
       "      <td>2024-04-17</td>\n",
       "      <td>2024-06-27</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06450366</th>\n",
       "      <td>MK-0616</td>\n",
       "      <td>A Phase 3, Randomized, Double-Blind Study to E...</td>\n",
       "      <td>Merck Sharp &amp; Dohme LLC</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>NOT_YET_RECRUITING</td>\n",
       "      <td>300</td>\n",
       "      <td>2024-07-15</td>\n",
       "      <td>Hypercholesterolemia</td>\n",
       "      <td>MK-0616, Ezetimibe, Bempedoic Acid, Placebo fo...</td>\n",
       "      <td>Mean Percent Change from Baseline in LDL-C at ...</td>\n",
       "      <td>Mean Percent Change from Baseline in Apolipopr...</td>\n",
       "      <td>No locations listed</td>\n",
       "      <td>2025-07-21</td>\n",
       "      <td>2024-06-10</td>\n",
       "      <td>2024-06-10</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05934292</th>\n",
       "      <td>MK-0616</td>\n",
       "      <td>An Open-Label, Single-Dose Clinical Study to E...</td>\n",
       "      <td>Merck Sharp &amp; Dohme LLC</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>33</td>\n",
       "      <td>2023-07-20</td>\n",
       "      <td>Hypercholesterolaemia</td>\n",
       "      <td>MK-0616</td>\n",
       "      <td>Panels A, B, and D: Area Under the Concentrati...</td>\n",
       "      <td>Dialysate Clearance (CLd) of MK-0616, Dialysat...</td>\n",
       "      <td>Hallandale Beach - United States, Miami - Unit...</td>\n",
       "      <td>2024-01-19</td>\n",
       "      <td>2023-07-06</td>\n",
       "      <td>2024-02-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05261126</th>\n",
       "      <td>MK-0616</td>\n",
       "      <td>A Phase 2b, Randomized, Double-Blind, Placebo-...</td>\n",
       "      <td>Merck Sharp &amp; Dohme LLC</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>381</td>\n",
       "      <td>2022-03-10</td>\n",
       "      <td>Hypercholesterolemia, Familial Hypercholestero...</td>\n",
       "      <td>MK-0616, Placebo</td>\n",
       "      <td>Percent Change From Baseline in Low-density Li...</td>\n",
       "      <td>Percent Change From Baseline in Apolipoprotein...</td>\n",
       "      <td>Beverly Hills - United States, Sacramento - Un...</td>\n",
       "      <td>2022-11-28</td>\n",
       "      <td>2022-03-02</td>\n",
       "      <td>2023-12-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05070390</th>\n",
       "      <td>MK-0616</td>\n",
       "      <td>An Open-Label Clinical Study to Evaluate the P...</td>\n",
       "      <td>Merck Sharp &amp; Dohme LLC</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>18</td>\n",
       "      <td>2021-11-16</td>\n",
       "      <td>Moderate Renal Impairment</td>\n",
       "      <td>MK-0616</td>\n",
       "      <td>Area Under the Concentration-Time Curve from T...</td>\n",
       "      <td>Number of Participants Experiencing an Adverse...</td>\n",
       "      <td>Hallandale Beach - United States, Knoxville - ...</td>\n",
       "      <td>2023-05-03</td>\n",
       "      <td>2021-10-07</td>\n",
       "      <td>2023-05-23</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05952869</th>\n",
       "      <td>MK-0616</td>\n",
       "      <td>A Phase 3, Randomized, Double-Blind, Placebo-C...</td>\n",
       "      <td>Merck Sharp &amp; Dohme LLC</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>270</td>\n",
       "      <td>2023-08-08</td>\n",
       "      <td>Hypercholesterolemia, Familial Hypercholestero...</td>\n",
       "      <td>MK-0616, Placebo</td>\n",
       "      <td>Mean percent change from baseline in low-densi...</td>\n",
       "      <td>Mean percent change from baseline in LDL-C at ...</td>\n",
       "      <td>Daphne - United States, Boca Raton - United St...</td>\n",
       "      <td>2025-04-28</td>\n",
       "      <td>2023-07-19</td>\n",
       "      <td>2024-03-13</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT05952856</th>\n",
       "      <td>MK-0616</td>\n",
       "      <td>A Phase 3, Randomized, Double-Blind, Placebo-C...</td>\n",
       "      <td>Merck Sharp &amp; Dohme LLC</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>2760</td>\n",
       "      <td>2023-08-10</td>\n",
       "      <td>Hypercholesterolemia, Familial Hypercholestero...</td>\n",
       "      <td>MK-0616, Placebo</td>\n",
       "      <td>Mean percent change from baseline in low-densi...</td>\n",
       "      <td>Mean percent change from baseline in LDL-C at ...</td>\n",
       "      <td>Daphne - United States, Foley - United States,...</td>\n",
       "      <td>2025-09-15</td>\n",
       "      <td>2023-07-19</td>\n",
       "      <td>2024-05-17</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>NCT06008756</th>\n",
       "      <td>MK-0616</td>\n",
       "      <td>Phase 3 Randomized, Placebo-Controlled Clinica...</td>\n",
       "      <td>Merck Sharp &amp; Dohme LLC</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>14550</td>\n",
       "      <td>2023-10-09</td>\n",
       "      <td>Arteriosclerosis, Hypercholesterolaemia</td>\n",
       "      <td>MK-0616, Placebo</td>\n",
       "      <td>Time to First Occurrence of Coronary Heart Dis...</td>\n",
       "      <td>Time to First Occurrence of 3-point MACE, Time...</td>\n",
       "      <td>Alexander City - United States, Birmingham - U...</td>\n",
       "      <td>2029-11-29</td>\n",
       "      <td>2023-08-24</td>\n",
       "      <td>2024-06-21</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                    Asset                                              Title  \\\n",
       "NCT ID                                                                         \n",
       "NCT01636492    Bitopertin  Single Oral Ascending Dose Study of Safety, To...   \n",
       "NCT05308472    Bitopertin  (AURORA) A Randomized, Double-blind, Placebo-C...   \n",
       "NCT01192880    Bitopertin  A Phase III, Multi-Center, Randomized, 24 Week...   \n",
       "NCT05883748    Bitopertin  An Open-Label, Long-Term Study to Investigate ...   \n",
       "NCT02019290    Bitopertin  A SINGLE CENTER, OPEN LABEL, FIXED SEQUENCE ST...   \n",
       "NCT05828108    Bitopertin  A Phase I/II, Intra-Patient Dose-Escalation St...   \n",
       "NCT03271541    Bitopertin  A Phase II, Single Arm, Multicenter, Proof-of-...   \n",
       "NCT01192906    Bitopertin  A Phase III, Multi-center, Randomized, 24 Week...   \n",
       "NCT01234779    Bitopertin  A Phase II, Multi-center, Randomized, 4-week, ...   \n",
       "NCT01235559    Bitopertin  Phase III, Multi-center, Randomized, 12-week, ...   \n",
       "NCT01235585    Bitopertin  Phase III, Multi-center, Randomized, 12-week, ...   \n",
       "NCT01674361    Bitopertin  A Phase II, Multicenter, Randomized, Double-Bl...   \n",
       "NCT06139055     GSBR-1290  A 2-part, Phase 1, Randomized Study to Evaluat...   \n",
       "NCT05893043     GSBR-1290  A Phase 1, Randomized, Double-blind, Placebo-c...   \n",
       "NCT05762471     GSBR-1290  A Phase 1b/2a, Randomized, Double-blind, Place...   \n",
       "NCT02709876          RP-1                                            Unknown   \n",
       "NCT04776889          RP-1  The Prognosis of Lipid Reprogramming With the ...   \n",
       "NCT06264180          RP-1  Randomized, Ph3 Clinical Study Comparing Vusol...   \n",
       "NCT05858229          RP-1  A Phase 1B Study of Intralesional Injection of...   \n",
       "NCT03767348          RP-1  An Open-Label, Multicenter, Phase 1/2 Study of...   \n",
       "NCT06395116          RP-1  \"Influence of Fabrication Technique on Microbi...   \n",
       "NCT02786381          RP-1  Idylla Respiratory (IFV-RSV) Panel Clinical Te...   \n",
       "NCT06216938          RP-1  Phase I Pilot Study of RP1 in Primary Melanoma...   \n",
       "NCT04349436          RP-1  An Open-Label, Multicenter, Phase 1B/2 Study o...   \n",
       "NCT04050436          RP-1  A Randomized, Controlled, Open-Label, Phase 2 ...   \n",
       "NCT04960579          RP-1  Open-Label, Multicenter, Phase 1 Study to Asse...   \n",
       "NCT03999021          RP-1  A Phase 1 Open-Label Extension Study to Assess...   \n",
       "NCT03063021          RP-1  A Phase 1 Open Label Dose Ranging Study to Ass...   \n",
       "NCT06067061          RP-1  \"neoBREASTIM\": A Phase 2 Study of Atezolizumab...   \n",
       "NCT04006457  Ritlecitinib  A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM ...   \n",
       "NCT06163326  Ritlecitinib  A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSE-UP TI...   \n",
       "NCT05879458  Ritlecitinib  A Single-center, Single-arm, Open-label Phase ...   \n",
       "NCT05128058  Ritlecitinib  AN OPEN LABEL, PHASE 1, TWO-ARM STUDY TO ASSES...   \n",
       "NCT05743244  Ritlecitinib  A Phase 2 Multi-Center, Randomized, Double-Bli...   \n",
       "NCT05852340  Ritlecitinib  A PHASE 1, RANDOMIZED, OPEN-LABEL, CROSSOVER S...   \n",
       "NCT04655040  Ritlecitinib  A PHASE 1, 2-PERIOD, FIXED-SEQUENCE, MULTIPLE-...   \n",
       "NCT06172348  Ritlecitinib  A PHASE 1, OPEN-LABEL STUDY IN HEALTHY PARTICI...   \n",
       "NCT05583526  Ritlecitinib  A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PL...   \n",
       "NCT06373458  Ritlecitinib  A Single-Center, Two-Arm, Open-Label Phase IIA...   \n",
       "NCT05549934  Ritlecitinib  A Pilot Study to Assess Safety and Biomarker R...   \n",
       "NCT05097716  Ritlecitinib  PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD ...   \n",
       "NCT05040295  Ritlecitinib  A PHASE 1, RANDOMIZED, OPEN-LABEL, CROSS-OVER,...   \n",
       "NCT04413617  Ritlecitinib  A 24-WEEK RANDOMIZED, DOUBLE-BLIND, PARALLEL G...   \n",
       "NCT04517864  Ritlecitinib  A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-...   \n",
       "NCT03732807  Ritlecitinib  A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO...   \n",
       "NCT06072183  Ritlecitinib  A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PL...   \n",
       "NCT05636293  Ritlecitinib  Double Blind, Placebo-controlled Trial to Esta...   \n",
       "NCT05650333  Ritlecitinib  AN INTERVENTIONAL PK, PD, PHASE 1, OPEN-LABEL ...   \n",
       "NCT06369454  Ritlecitinib  A PHASE 1, RANDOMIZED, OPEN-LABEL, 2-SEQUENCE,...   \n",
       "NCT06450366       MK-0616  A Phase 3, Randomized, Double-Blind Study to E...   \n",
       "NCT05934292       MK-0616  An Open-Label, Single-Dose Clinical Study to E...   \n",
       "NCT05261126       MK-0616  A Phase 2b, Randomized, Double-Blind, Placebo-...   \n",
       "NCT05070390       MK-0616  An Open-Label Clinical Study to Evaluate the P...   \n",
       "NCT05952869       MK-0616  A Phase 3, Randomized, Double-Blind, Placebo-C...   \n",
       "NCT05952856       MK-0616  A Phase 3, Randomized, Double-Blind, Placebo-C...   \n",
       "NCT06008756       MK-0616  Phase 3 Randomized, Placebo-Controlled Clinica...   \n",
       "\n",
       "                                                  Lead Sponsor  \\\n",
       "NCT ID                                                           \n",
       "NCT01636492                                  Hoffmann-La Roche   \n",
       "NCT05308472                                 Disc Medicine, Inc   \n",
       "NCT01192880                                  Hoffmann-La Roche   \n",
       "NCT05883748                                 Disc Medicine, Inc   \n",
       "NCT02019290                                  Hoffmann-La Roche   \n",
       "NCT05828108  National Heart, Lung, and Blood Institute (NHLBI)   \n",
       "NCT03271541                                  Hoffmann-La Roche   \n",
       "NCT01192906                                  Hoffmann-La Roche   \n",
       "NCT01234779                                  Hoffmann-La Roche   \n",
       "NCT01235559                                  Hoffmann-La Roche   \n",
       "NCT01235585                                  Hoffmann-La Roche   \n",
       "NCT01674361                                  Hoffmann-La Roche   \n",
       "NCT06139055                                Gasherbrum Bio, Inc   \n",
       "NCT05893043                                Gasherbrum Bio, Inc   \n",
       "NCT05762471                                Gasherbrum Bio, Inc   \n",
       "NCT02709876                                  Stem Cells Arabia   \n",
       "NCT04776889                   National Cancer Institute, Egypt   \n",
       "NCT06264180                                     Replimune Inc.   \n",
       "NCT05858229                                    Sherrif Ibrahim   \n",
       "NCT03767348                                     Replimune Inc.   \n",
       "NCT06395116                                Menoufia University   \n",
       "NCT02786381                Janssen Pharmaceutica N.V., Belgium   \n",
       "NCT06216938                                        Yana Najjar   \n",
       "NCT04349436                                     Replimune Inc.   \n",
       "NCT04050436                                     Replimune Inc.   \n",
       "NCT04960579                         Poseida Therapeutics, Inc.   \n",
       "NCT03999021                           Johns Hopkins University   \n",
       "NCT03063021                           Johns Hopkins University   \n",
       "NCT06067061                                     Institut Curie   \n",
       "NCT04006457                                             Pfizer   \n",
       "NCT06163326                                             Pfizer   \n",
       "NCT05879458            Icahn School of Medicine at Mount Sinai   \n",
       "NCT05128058                                             Pfizer   \n",
       "NCT05743244  National Institute of Diabetes and Digestive a...   \n",
       "NCT05852340                                             Pfizer   \n",
       "NCT04655040                                             Pfizer   \n",
       "NCT06172348                                             Pfizer   \n",
       "NCT05583526                                             Pfizer   \n",
       "NCT06373458            Icahn School of Medicine at Mount Sinai   \n",
       "NCT05549934                                       Emma Guttman   \n",
       "NCT05097716                                             Pfizer   \n",
       "NCT05040295                                             Pfizer   \n",
       "NCT04413617                                             Pfizer   \n",
       "NCT04517864                                             Pfizer   \n",
       "NCT03732807                                             Pfizer   \n",
       "NCT06072183                                             Pfizer   \n",
       "NCT05636293                     Massachusetts General Hospital   \n",
       "NCT05650333                                             Pfizer   \n",
       "NCT06369454                                             Pfizer   \n",
       "NCT06450366                            Merck Sharp & Dohme LLC   \n",
       "NCT05934292                            Merck Sharp & Dohme LLC   \n",
       "NCT05261126                            Merck Sharp & Dohme LLC   \n",
       "NCT05070390                            Merck Sharp & Dohme LLC   \n",
       "NCT05952869                            Merck Sharp & Dohme LLC   \n",
       "NCT05952856                            Merck Sharp & Dohme LLC   \n",
       "NCT06008756                            Merck Sharp & Dohme LLC   \n",
       "\n",
       "                    Acronym           Overall Status Enrollment  Start Date  \\\n",
       "NCT ID                                                                        \n",
       "NCT01636492         Unknown                COMPLETED         71     2005-11   \n",
       "NCT05308472         Unknown    ACTIVE_NOT_RECRUITING         75  2022-10-31   \n",
       "NCT01192880         Unknown                COMPLETED        625     2010-11   \n",
       "NCT05883748         Unknown  ENROLLING_BY_INVITATION        200  2023-08-31   \n",
       "NCT02019290         Unknown                WITHDRAWN          0  2014-02-10   \n",
       "NCT05828108         Unknown               RECRUITING         30  2023-07-25   \n",
       "NCT03271541         Unknown                COMPLETED         12  2017-10-26   \n",
       "NCT01192906         Unknown                COMPLETED        624     2010-12   \n",
       "NCT01234779         Unknown                COMPLETED        301     2011-02   \n",
       "NCT01235559         Unknown                COMPLETED        604     2010-12   \n",
       "NCT01235585         Unknown                COMPLETED        597     2010-12   \n",
       "NCT01674361         Unknown                COMPLETED         99  2012-12-31   \n",
       "NCT06139055         Unknown    ACTIVE_NOT_RECRUITING         70  2023-10-02   \n",
       "NCT05893043         Unknown                COMPLETED         18  2023-04-24   \n",
       "NCT05762471         Unknown                COMPLETED        142  2023-01-09   \n",
       "NCT02709876         Unknown                  UNKNOWN         50     2014-04   \n",
       "NCT04776889         Unknown                COMPLETED         70  2019-01-15   \n",
       "NCT06264180         Unknown       NOT_YET_RECRUITING        400  2024-06-01   \n",
       "NCT05858229         Unknown               RECRUITING         12  2023-06-16   \n",
       "NCT03767348          IGNYTE               RECRUITING        340  2017-09-20   \n",
       "NCT06395116         Unknown    ACTIVE_NOT_RECRUITING         60  2023-01-20   \n",
       "NCT02786381             RP1                COMPLETED        213     2015-11   \n",
       "NCT06216938         Unknown               RECRUITING         25  2024-02-02   \n",
       "NCT04349436         ARTACUS               RECRUITING         65  2020-05-15   \n",
       "NCT04050436         CERPASS    ACTIVE_NOT_RECRUITING        231  2019-10-08   \n",
       "NCT04960579              MM               RECRUITING        231  2022-05-05   \n",
       "NCT03999021         Unknown    ACTIVE_NOT_RECRUITING         30  2019-06-24   \n",
       "NCT03063021       FIGHT-RP1                COMPLETED         30  2017-02-15   \n",
       "NCT06067061     neoBREASTIM               RECRUITING         51  2024-04-05   \n",
       "NCT04006457      ALLEGRO-LT    ACTIVE_NOT_RECRUITING       1051  2019-07-18   \n",
       "NCT06163326  Tranquillo LTE               RECRUITING        400  2024-01-19   \n",
       "NCT05879458         Unknown               RECRUITING         20  2023-05-17   \n",
       "NCT05128058         Unknown                COMPLETED         16  2021-10-22   \n",
       "NCT05743244         Unknown               RECRUITING         78  2023-10-19   \n",
       "NCT05852340         Unknown                COMPLETED         12  2023-05-09   \n",
       "NCT04655040         Unknown                COMPLETED         12  2020-12-18   \n",
       "NCT06172348         Unknown                COMPLETED         12  2024-02-01   \n",
       "NCT05583526      Tranquillo               RECRUITING        600  2022-12-01   \n",
       "NCT06373458         Unknown               RECRUITING         30  2024-06-30   \n",
       "NCT05549934         Unknown               RECRUITING         50  2022-12-15   \n",
       "NCT05097716         Unknown                COMPLETED         12  2021-11-02   \n",
       "NCT05040295         Unknown                COMPLETED         12  2021-09-10   \n",
       "NCT04413617         Unknown                COMPLETED        460  2020-07-29   \n",
       "NCT04517864       Allegro2a               TERMINATED         71  2020-09-15   \n",
       "NCT03732807    ALLEGRO-2b/3                COMPLETED        718  2018-12-03   \n",
       "NCT06072183    Tranquillo 2               RECRUITING       1450  2023-11-08   \n",
       "NCT05636293         Unknown               RECRUITING         30  2023-03-01   \n",
       "NCT05650333         Unknown                COMPLETED         15  2023-03-02   \n",
       "NCT06369454         Unknown    ACTIVE_NOT_RECRUITING          6  2024-05-03   \n",
       "NCT06450366         Unknown       NOT_YET_RECRUITING        300  2024-07-15   \n",
       "NCT05934292         Unknown                COMPLETED         33  2023-07-20   \n",
       "NCT05261126         Unknown                COMPLETED        381  2022-03-10   \n",
       "NCT05070390         Unknown                COMPLETED         18  2021-11-16   \n",
       "NCT05952869         Unknown    ACTIVE_NOT_RECRUITING        270  2023-08-08   \n",
       "NCT05952856         Unknown    ACTIVE_NOT_RECRUITING       2760  2023-08-10   \n",
       "NCT06008756         Unknown               RECRUITING      14550  2023-10-09   \n",
       "\n",
       "                                                    Conditions  \\\n",
       "NCT ID                                                           \n",
       "NCT01636492                                  Healthy Volunteer   \n",
       "NCT05308472                      Erythropoietic Protoporphyria   \n",
       "NCT01192880                                      Schizophrenia   \n",
       "NCT05883748                      Erythropoietic Protoporphyria   \n",
       "NCT02019290                                  Healthy Volunteer   \n",
       "NCT05828108   Steroid-refractory Diamond-Blackfan Anemia (DBA)   \n",
       "NCT03271541                                   Beta-Thalassemia   \n",
       "NCT01192906                                      Schizophrenia   \n",
       "NCT01234779                                      Schizophrenia   \n",
       "NCT01235559                                      Schizophrenia   \n",
       "NCT01235585                                      Schizophrenia   \n",
       "NCT01674361                      Obsessive-Compulsive Disorder   \n",
       "NCT06139055                                 Healthy Volunteers   \n",
       "NCT05893043                                 Healthy Volunteers   \n",
       "NCT05762471     Overweight or Obesity, Type2 Diabetes Mellitus   \n",
       "NCT02709876                               Retinitis Pigmentosa   \n",
       "NCT04776889                         Prostate Cancer Metastatic   \n",
       "NCT06264180                                  Advanced Melanoma   \n",
       "NCT05858229                       Squamous Cell Carcinoma, RP1   \n",
       "NCT03767348  Cancer, Melanoma (Skin), Mismatch Repair Defic...   \n",
       "NCT06395116  Inflammatory Response, Microbial Colonization,...   \n",
       "NCT02786381  Respiratory Tract Infections, Influenza, Human...   \n",
       "NCT06216938                                           Melanoma   \n",
       "NCT04349436  Cutaneous Squamous Cell Carcinoma, Merkel Cell...   \n",
       "NCT04050436  Cutaneous Squamous Cell Carcinoma, Advanced Cu...   \n",
       "NCT04960579                                   Multiple Myeloma   \n",
       "NCT03999021                               Retinitis Pigmentosa   \n",
       "NCT03063021                               Retinitis Pigmentosa   \n",
       "NCT06067061                   Triple Negative Breast Neoplasms   \n",
       "NCT04006457                                    Alopecia Areata   \n",
       "NCT06163326                                           Vitiligo   \n",
       "NCT05879458           CTCL, Mycosis Fungoides, Sezary Syndrome   \n",
       "NCT05128058                                            Healthy   \n",
       "NCT05743244                          Diabetes Mellitus, Type 1   \n",
       "NCT05852340        Healthy Volunteers, Adult, Pharmacokinetics   \n",
       "NCT04655040                               Healthy Participants   \n",
       "NCT06172348                                 Healthy Volunteers   \n",
       "NCT05583526  Stable Nonsegmental Vitiligo, Active Nonsegmen...   \n",
       "NCT06373458                                             Keloid   \n",
       "NCT05549934                               Cicatricial Alopecia   \n",
       "NCT05097716                                 Healthy Volunteers   \n",
       "NCT05040295                               Healthy Participants   \n",
       "NCT04413617                               Rheumatoid Arthritis   \n",
       "NCT04517864                                    Alopecia Areata   \n",
       "NCT03732807                                    Alopecia Areata   \n",
       "NCT06072183  Stable Nonsegmental Vitiligo, Active Nonsegmen...   \n",
       "NCT05636293                                     Celiac Disease   \n",
       "NCT05650333                                    Alopecia Areata   \n",
       "NCT06369454                                 Healthy Volunteers   \n",
       "NCT06450366                               Hypercholesterolemia   \n",
       "NCT05934292                              Hypercholesterolaemia   \n",
       "NCT05261126  Hypercholesterolemia, Familial Hypercholestero...   \n",
       "NCT05070390                          Moderate Renal Impairment   \n",
       "NCT05952869  Hypercholesterolemia, Familial Hypercholestero...   \n",
       "NCT05952856  Hypercholesterolemia, Familial Hypercholestero...   \n",
       "NCT06008756            Arteriosclerosis, Hypercholesterolaemia   \n",
       "\n",
       "                                                 Interventions  \\\n",
       "NCT ID                                                           \n",
       "NCT01636492                                bitopertin, placebo   \n",
       "NCT05308472           DISC-1459, DISC-1459, Placebo, DISC-1459   \n",
       "NCT01192880                Placebo, Bitopertin, Antipsychotics   \n",
       "NCT05883748                               DISC-1459, DISC-1459   \n",
       "NCT02019290                              Midazolam, bitopertin   \n",
       "NCT05828108                                         Bitopertin   \n",
       "NCT03271541                                         Bitopertin   \n",
       "NCT01192906  Placebo, bitopertin [RO4917838], bitopertin [R...   \n",
       "NCT01234779  bitopertin [RO4917838], bitopertin [RO4917838]...   \n",
       "NCT01235559  Placebo, bitopertin [RO4917838] level 1, bitop...   \n",
       "NCT01235585  Placebo, bitopertin [RO4917838], bitopertin [R...   \n",
       "NCT01674361                          Bitopertin, Placebo, SSRI   \n",
       "NCT06139055  GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo...   \n",
       "NCT05893043                                 GSBR-1290, Placebo   \n",
       "NCT05762471                                 GSBR-1290, Placebo   \n",
       "NCT02709876                          Stem Cell Transplantation   \n",
       "NCT04776889             Rosuvastatin 20mg, surgical castration   \n",
       "NCT06264180  Vusolimogene Oderparepvec, Nivolumab, Nivoluma...   \n",
       "NCT05858229                                                RP1   \n",
       "NCT03767348                                     RP1, nivolumab   \n",
       "NCT06395116                              Denture base material   \n",
       "NCT02786381                            No interventions listed   \n",
       "NCT06216938                    Vusolimogene oderparepvec (RP1)   \n",
       "NCT04349436      RP1, intra-tumoral injection, oncolytic virus   \n",
       "NCT04050436                                    Cemiplimab, RP1   \n",
       "NCT04960579                P-BCMA-ALLO1 CAR-T cells, Rimiducid   \n",
       "NCT03999021                           NAC effervescent tablets   \n",
       "NCT03063021                            N-Acetyl Cysteine (NAC)   \n",
       "NCT06067061                                 Atezolizumab + RP1   \n",
       "NCT04006457  PF-06651600, Tetanus and diphtheria toxoids an...   \n",
       "NCT06163326         Ritlecitinib, Ritlecitinib 100 mg, Placebo   \n",
       "NCT05879458                                       Ritlecitinib   \n",
       "NCT05128058            Ritlecitinib 50 mg, Ritlecitinib 200 mg   \n",
       "NCT05743244  Abrocitinib 200 MG Oral Tablet, Ritlecitinib, ...   \n",
       "NCT05852340                                       Ritlecitinib   \n",
       "NCT04655040                             Caffeine, Ritlecitinib   \n",
       "NCT06172348                                       Ritlecitinib   \n",
       "NCT05583526                              Ritlecitinib, Placebo   \n",
       "NCT06373458                                       Ritlecitinib   \n",
       "NCT05549934                                        PF-06651600   \n",
       "NCT05097716                          Ritlecitinib, Tolbutamide   \n",
       "NCT05040295           ritlecitinib, ritlecitinib, ritlecitinib   \n",
       "NCT04413617              PF-06650833, PF-06651600, Tofacitinib   \n",
       "NCT04517864                               PF-06651600, Placebo   \n",
       "NCT03732807  PF-06651600 Induction Dose, PF-06651600 Mainte...   \n",
       "NCT06072183                Ritlecitinib, Ritlecitinib, Placebo   \n",
       "NCT05636293                      Ritlecitinib, Placebo, Gluten   \n",
       "NCT05650333                                 Ritlecitinib 20 mg   \n",
       "NCT06369454                                       Ritlecitinib   \n",
       "NCT06450366  MK-0616, Ezetimibe, Bempedoic Acid, Placebo fo...   \n",
       "NCT05934292                                            MK-0616   \n",
       "NCT05261126                                   MK-0616, Placebo   \n",
       "NCT05070390                                            MK-0616   \n",
       "NCT05952869                                   MK-0616, Placebo   \n",
       "NCT05952856                                   MK-0616, Placebo   \n",
       "NCT06008756                                   MK-0616, Placebo   \n",
       "\n",
       "                                            Primary Outcome(s)  \\\n",
       "NCT ID                                                           \n",
       "NCT01636492                Safety: Incidence of adverse events   \n",
       "NCT05308472  Percent change from baseline in whole blood me...   \n",
       "NCT01192880  Mean Change From Baseline in the Positive and ...   \n",
       "NCT05883748  Incidence of treatment-emergent adverse events...   \n",
       "NCT02019290  Change in plasma area under the concentration-...   \n",
       "NCT05828108                                   Rate of response   \n",
       "NCT03271541  Safety Outcome: Percentage of Participants wit...   \n",
       "NCT01192906  Efficacy (PANSS negative symptoms factor score...   \n",
       "NCT01234779  Change in Positive and Negative Syndrome Scale...   \n",
       "NCT01235559  Positive symptoms factor score assessed by Pos...   \n",
       "NCT01235585  Positive symptoms factor score assessed by Pos...   \n",
       "NCT01674361  Change From Baseline in Total Score on Yale-Br...   \n",
       "NCT06139055  Part 1: Analysis of Maximum Observed Plasma Co...   \n",
       "NCT05893043  Number of Participants With Adverse Events (AE...   \n",
       "NCT05762471  Incidence, severity and relationship of AE/SAE...   \n",
       "NCT02709876                         ETDRS Visual acuity change   \n",
       "NCT04776889  Lipid profile, Aggressiveness parameters, Aggr...   \n",
       "NCT06264180                              Overall Survival (OS)   \n",
       "NCT05858229  Evaluate degree of pathologic response at 16 w...   \n",
       "NCT03767348  Percentage of adverse events (AEs), Percentage...   \n",
       "NCT06395116                                  Biofilm formation   \n",
       "NCT02786381  Product performance as measured by positive an...   \n",
       "NCT06216938       Rate of Sentinel Lymph Node (SLN) Positivity   \n",
       "NCT04349436  Primary Safety Outcome Measure, Primary Effica...   \n",
       "NCT04050436  Objective Response Rate (ORR) according to bli...   \n",
       "NCT04960579  Phase 1 Part 1: Assess the safety and maximum ...   \n",
       "NCT03999021  Blood Pressure (mmHg), Tolerability of N-Acety...   \n",
       "NCT03063021  Assessment of safety and tolerability of N-Ace...   \n",
       "NCT06067061  Safety of the combination Atezolizumab plus RP...   \n",
       "NCT04006457  Number of subjects reporting treatment-emergen...   \n",
       "NCT06163326  Incidence of treatment-emergent adverse events...   \n",
       "NCT05879458  Change in Modified Severity Weighted Assessmen...   \n",
       "NCT05128058  Percent Target Occupancy for JAK3, Percent Tar...   \n",
       "NCT05743244  The area under the stimulated C-peptide curve ...   \n",
       "NCT05852340  Maximum plasma concentration (Cmax), Area unde...   \n",
       "NCT04655040  Area under the plasma concentration-time profi...   \n",
       "NCT06172348  Maximum plasma concentration (Cmax), Area unde...   \n",
       "NCT05583526  US only Co-Primary Endpoints: Response based o...   \n",
       "NCT06373458  Recurrence Rate, Change in Detroid Keloid Scal...   \n",
       "NCT05549934  Number of Treatment-Emergent Adverse Events, S...   \n",
       "NCT05097716  Maximum Plasma Concentration (Cmax) of Tolbuta...   \n",
       "NCT05040295  Area Under the Plasma Concentration-Time Profi...   \n",
       "NCT04413617  Change From Baseline (BL) in Disease Activity ...   \n",
       "NCT04517864  Change From Baseline in I-V Interwave Latency ...   \n",
       "NCT03732807  Percentage of Participants With an Absolute Se...   \n",
       "NCT06072183  US only Co-Primary Endpoints: Response based o...   \n",
       "NCT05636293  Change in Small Intestinal Histology based on ...   \n",
       "NCT05650333  Area under the plasma concentration time profi...   \n",
       "NCT06369454  Site of capsule disintegration and MR microsph...   \n",
       "NCT06450366  Mean Percent Change from Baseline in LDL-C at ...   \n",
       "NCT05934292  Panels A, B, and D: Area Under the Concentrati...   \n",
       "NCT05261126  Percent Change From Baseline in Low-density Li...   \n",
       "NCT05070390  Area Under the Concentration-Time Curve from T...   \n",
       "NCT05952869  Mean percent change from baseline in low-densi...   \n",
       "NCT05952856  Mean percent change from baseline in low-densi...   \n",
       "NCT06008756  Time to First Occurrence of Coronary Heart Dis...   \n",
       "\n",
       "                                          Secondary Outcome(s)  \\\n",
       "NCT ID                                                           \n",
       "NCT01636492  Pharmacokinetics: Area under the concentration...   \n",
       "NCT05308472  Total hours of sunlight exposure to skin on da...   \n",
       "NCT01192880  Mean Change from Baseline in the Personal and ...   \n",
       "NCT05883748  Change from baseline in daily daylight toleran...   \n",
       "NCT02019290  Change in 1'-hydroxymidazolam plasma AUC after...   \n",
       "NCT05828108  Rate of relapse, Long-term safety of drug, Tol...   \n",
       "NCT03271541  Apparent Clearance of Bitopertin, Volume of Di...   \n",
       "NCT01192906                       No secondary outcomes listed   \n",
       "NCT01234779  Clinical response, defined as at least 30% or ...   \n",
       "NCT01235559  Symptom domains of schizophrenia using Positiv...   \n",
       "NCT01235585  Symptom domains of schizophrenia using Positiv...   \n",
       "NCT01674361  Change From Baseline in Clinical Global Impres...   \n",
       "NCT06139055  Part 1: Number of Participants With Adverse Ev...   \n",
       "NCT05893043  Analysis of Maximum Observed Plasma Concentrat...   \n",
       "NCT05762471  Analysis of Cmax at specified timepoints predo...   \n",
       "NCT02709876  Quality of Life: Questionnaire VFQ-25 (Visual ...   \n",
       "NCT04776889  short-term clinical outcome, short-term clinic...   \n",
       "NCT06264180  Progression Free Survival (PFS), Objective Res...   \n",
       "NCT05858229  Evaluate the duration of response, Evaluate pr...   \n",
       "NCT03767348  Percentage of biologic activity, Percentage su...   \n",
       "NCT06395116                       No secondary outcomes listed   \n",
       "NCT02786381                       No secondary outcomes listed   \n",
       "NCT06216938  Incidence of all treatment-emergent adverse ev...   \n",
       "NCT04349436  Duration of response (DOR) by investigator amo...   \n",
       "NCT04050436  Progression Free Survival (PFS) by blinded ind...   \n",
       "NCT04960579  The safety of P-BCMA-ALLO1, The anti-myeloma e...   \n",
       "NCT03999021  Change in best corrected visual acuity (BCVA),...   \n",
       "NCT03063021  Change from baseline aqueous and serum carbony...   \n",
       "NCT06067061  Response rate of RCB Score <= 1 at three cycle...   \n",
       "NCT04006457  Percentage of subjects with an absolute Severi...   \n",
       "NCT06163326  Response based on T-VASI75 at weeks 4, 8, 12, ...   \n",
       "NCT05879458  Change in Modified Severity Weighted Assessmen...   \n",
       "NCT05128058  Maximum Observed Plasma Concentration (Cmax) o...   \n",
       "NCT05743244                       No secondary outcomes listed   \n",
       "NCT05852340    Number of participants reporting adverse events   \n",
       "NCT04655040  Incidence of treatment-emergent adverse events...   \n",
       "NCT06172348  Frequency of adverse events, Frequency of abno...   \n",
       "NCT05583526  US-Only: Response based on F-VASI75 at 24, 26 ...   \n",
       "NCT06373458  Change in Peak keloid tension, Change in Detro...   \n",
       "NCT05549934  Change in Ct values of mRNA levels of CXCR3, C...   \n",
       "NCT05097716  Number of Participants With Treatment-Emergent...   \n",
       "NCT05040295  Number of Participants With Treatment-Emergent...   \n",
       "NCT04413617  DAS28-CRP Remission (<2.6) Rates at Week 24, N...   \n",
       "NCT04517864  Change From Baseline in I-V Interwave Latency ...   \n",
       "NCT03732807  Percentage of Participants With an Absolute SA...   \n",
       "NCT06072183  Response based on F-VASI75 at 24 and 36 weeks,...   \n",
       "NCT05636293  Serology, Changes in Small Intestinal Histolog...   \n",
       "NCT05650333  Maximum Observed Plasma Concentration (Cmax), ...   \n",
       "NCT06369454  Maximum plasma concentration (Cmax), Area unde...   \n",
       "NCT06450366  Mean Percent Change from Baseline in Apolipopr...   \n",
       "NCT05934292  Dialysate Clearance (CLd) of MK-0616, Dialysat...   \n",
       "NCT05261126  Percent Change From Baseline in Apolipoprotein...   \n",
       "NCT05070390  Number of Participants Experiencing an Adverse...   \n",
       "NCT05952869  Mean percent change from baseline in LDL-C at ...   \n",
       "NCT05952856  Mean percent change from baseline in LDL-C at ...   \n",
       "NCT06008756  Time to First Occurrence of 3-point MACE, Time...   \n",
       "\n",
       "                                                     Locations  \\\n",
       "NCT ID                                                           \n",
       "NCT01636492                         Christchurch - New Zealand   \n",
       "NCT05308472  Birmingham - United States, San Francisco - Un...   \n",
       "NCT01192880  Costa Mesa - United States, Escondido - United...   \n",
       "NCT05883748  Birmingham - United States, San Francisco - Un...   \n",
       "NCT02019290                                No locations listed   \n",
       "NCT05828108                           Bethesda - United States   \n",
       "NCT03271541  Genova - Italy, Milano - Italy, Baabda - Leban...   \n",
       "NCT01192906  Carson - United States, Oceanside - United Sta...   \n",
       "NCT01234779  Little Rock - United States, Cerritos - United...   \n",
       "NCT01235559  Costa Mesa - United States, Escondido - United...   \n",
       "NCT01235585  Carson - United States, Garden Grove - United ...   \n",
       "NCT01674361  Oceanside - United States, Stanford - United S...   \n",
       "NCT06139055  Miami - United States, Miami - United States, ...   \n",
       "NCT05893043                            Anaheim - United States   \n",
       "NCT05762471  Anaheim - United States, Chula Vista - United ...   \n",
       "NCT02709876                                     Amman - Jordan   \n",
       "NCT04776889                                      Cairo - Egypt   \n",
       "NCT06264180                                No locations listed   \n",
       "NCT05858229                             Victor - United States   \n",
       "NCT03767348  Birmingham - United States, Gilbert - United S...   \n",
       "NCT06395116                                   Mansoura - Egypt   \n",
       "NCT02786381                          Pensacola - United States   \n",
       "NCT06216938                         Pittsburgh - United States   \n",
       "NCT04349436  Phoenix - United States, La Jolla - United Sta...   \n",
       "NCT04050436  La Jolla - United States, Los Angeles - United...   \n",
       "NCT04960579  San Diego - United States, San Francisco - Uni...   \n",
       "NCT03999021                          Baltimore - United States   \n",
       "NCT03063021                          Baltimore - United States   \n",
       "NCT06067061                                     Paris - France   \n",
       "NCT04006457  Birmingham - United States, Birmingham - Unite...   \n",
       "NCT06163326  Encinitas - United States, Huntington Beach - ...   \n",
       "NCT05879458                           New York - United States   \n",
       "NCT05128058                          New Haven - United States   \n",
       "NCT05743244  Orange - United States, Palo Alto - United Sta...   \n",
       "NCT05852340                                 Brussels - Belgium   \n",
       "NCT04655040                          New Haven - United States   \n",
       "NCT06172348                                 Brussels - Belgium   \n",
       "NCT05583526  Birmingham - United States, Birmingham - Unite...   \n",
       "NCT06373458                           New York - United States   \n",
       "NCT05549934                           New York - United States   \n",
       "NCT05097716                          New Haven - United States   \n",
       "NCT05040295                          New Haven - United States   \n",
       "NCT04413617  Pleven - Bulgaria, Plovdiv - Bulgaria, Plovdiv...   \n",
       "NCT04517864  Huntington Beach - United States, Irvine - Uni...   \n",
       "NCT03732807  Birmingham - United States, Birmingham - Unite...   \n",
       "NCT06072183  Birmingham - United States, Birmingham - Unite...   \n",
       "NCT05636293                             Boston - United States   \n",
       "NCT05650333  Encinitas - United States, Coral Gables - Unit...   \n",
       "NCT06369454                          Lexington - United States   \n",
       "NCT06450366                                No locations listed   \n",
       "NCT05934292  Hallandale Beach - United States, Miami - Unit...   \n",
       "NCT05261126  Beverly Hills - United States, Sacramento - Un...   \n",
       "NCT05070390  Hallandale Beach - United States, Knoxville - ...   \n",
       "NCT05952869  Daphne - United States, Boca Raton - United St...   \n",
       "NCT05952856  Daphne - United States, Foley - United States,...   \n",
       "NCT06008756  Alexander City - United States, Birmingham - U...   \n",
       "\n",
       "            Primary Completion Date Study First Post Date  \\\n",
       "NCT ID                                                      \n",
       "NCT01636492                 2006-08            2012-07-10   \n",
       "NCT05308472              2024-02-20            2022-04-04   \n",
       "NCT01192880                 2014-07            2010-09-01   \n",
       "NCT05883748                 2028-06            2023-06-01   \n",
       "NCT02019290              2014-03-31            2013-12-24   \n",
       "NCT05828108              2029-05-01            2023-04-25   \n",
       "NCT03271541              2018-06-29            2017-09-05   \n",
       "NCT01192906                 2014-07            2010-09-01   \n",
       "NCT01234779                 2012-09            2010-11-04   \n",
       "NCT01235559                 2015-03            2010-11-05   \n",
       "NCT01235585                 2014-09            2010-11-05   \n",
       "NCT01674361              2015-04-30            2012-08-28   \n",
       "NCT06139055                 2024-03            2023-11-18   \n",
       "NCT05893043              2023-06-28            2023-06-07   \n",
       "NCT05762471              2024-04-11            2023-03-09   \n",
       "NCT02709876                 2020-09            2016-03-16   \n",
       "NCT04776889              2020-12-30            2021-03-02   \n",
       "NCT06264180              2029-01-01            2024-02-16   \n",
       "NCT05858229                 2025-12            2023-05-15   \n",
       "NCT03767348                 2024-11            2018-12-06   \n",
       "NCT06395116              2024-07-04            2024-05-01   \n",
       "NCT02786381                 2016-10            2016-06-01   \n",
       "NCT06216938              2026-01-31            2024-01-22   \n",
       "NCT04349436                 2027-09            2020-04-16   \n",
       "NCT04050436                 2025-09            2019-08-08   \n",
       "NCT04960579                 2027-12            2021-07-14   \n",
       "NCT03999021                 2026-08            2019-06-26   \n",
       "NCT03063021              2019-02-11            2017-02-24   \n",
       "NCT06067061              2026-04-05            2023-10-04   \n",
       "NCT04006457              2024-07-08            2019-07-05   \n",
       "NCT06163326              2027-01-30            2023-12-08   \n",
       "NCT05879458                 2026-04            2023-05-30   \n",
       "NCT05128058              2022-01-14            2021-11-19   \n",
       "NCT05743244              2026-06-30            2023-02-24   \n",
       "NCT05852340              2023-07-12            2023-05-10   \n",
       "NCT04655040              2021-03-05            2020-12-04   \n",
       "NCT06172348              2024-03-28            2023-12-15   \n",
       "NCT05583526              2025-07-28            2022-10-17   \n",
       "NCT06373458                 2026-03            2024-04-18   \n",
       "NCT05549934                 2024-12            2022-09-22   \n",
       "NCT05097716              2022-01-10            2021-10-28   \n",
       "NCT05040295              2021-11-19            2021-09-10   \n",
       "NCT04413617              2022-02-07            2020-06-04   \n",
       "NCT04517864              2022-01-04            2020-08-18   \n",
       "NCT03732807              2020-12-31            2018-11-07   \n",
       "NCT06072183              2027-07-14            2023-10-10   \n",
       "NCT05636293              2025-08-01            2022-12-05   \n",
       "NCT05650333              2023-08-11            2022-12-14   \n",
       "NCT06369454              2024-08-02            2024-04-17   \n",
       "NCT06450366              2025-07-21            2024-06-10   \n",
       "NCT05934292              2024-01-19            2023-07-06   \n",
       "NCT05261126              2022-11-28            2022-03-02   \n",
       "NCT05070390              2023-05-03            2021-10-07   \n",
       "NCT05952869              2025-04-28            2023-07-19   \n",
       "NCT05952856              2025-09-15            2023-07-19   \n",
       "NCT06008756              2029-11-29            2023-08-24   \n",
       "\n",
       "            Last Update Post Date      Study Type          Phases  \n",
       "NCT ID                                                             \n",
       "NCT01636492            2016-11-02  INTERVENTIONAL          PHASE1  \n",
       "NCT05308472            2024-04-15  INTERVENTIONAL          PHASE2  \n",
       "NCT01192880            2017-02-15  INTERVENTIONAL          PHASE3  \n",
       "NCT05883748            2024-02-22  INTERVENTIONAL  PHASE2, PHASE3  \n",
       "NCT02019290            2017-10-25  INTERVENTIONAL          PHASE1  \n",
       "NCT05828108            2024-04-10  INTERVENTIONAL  PHASE1, PHASE2  \n",
       "NCT03271541            2018-10-05  INTERVENTIONAL          PHASE2  \n",
       "NCT01192906            2016-11-02  INTERVENTIONAL          PHASE3  \n",
       "NCT01234779            2016-11-02  INTERVENTIONAL          PHASE2  \n",
       "NCT01235559            2016-11-02  INTERVENTIONAL          PHASE3  \n",
       "NCT01235585            2016-11-02  INTERVENTIONAL          PHASE3  \n",
       "NCT01674361            2017-08-02  INTERVENTIONAL          PHASE2  \n",
       "NCT06139055            2024-02-15  INTERVENTIONAL          PHASE1  \n",
       "NCT05893043            2023-07-14  INTERVENTIONAL          PHASE1  \n",
       "NCT05762471            2024-04-25  INTERVENTIONAL  PHASE1, PHASE2  \n",
       "NCT02709876            2020-03-17  INTERVENTIONAL  PHASE1, PHASE2  \n",
       "NCT04776889            2021-03-02  INTERVENTIONAL          PHASE4  \n",
       "NCT06264180            2024-02-16  INTERVENTIONAL          PHASE3  \n",
       "NCT05858229            2024-03-26  INTERVENTIONAL  PHASE1, PHASE2  \n",
       "NCT03767348            2023-08-02  INTERVENTIONAL          PHASE2  \n",
       "NCT06395116            2024-05-01   OBSERVATIONAL   Not Available  \n",
       "NCT02786381            2016-11-22   OBSERVATIONAL   Not Available  \n",
       "NCT06216938            2024-03-04  INTERVENTIONAL    EARLY_PHASE1  \n",
       "NCT04349436            2024-03-01  INTERVENTIONAL  PHASE1, PHASE2  \n",
       "NCT04050436            2024-04-02  INTERVENTIONAL          PHASE2  \n",
       "NCT04960579            2024-06-21  INTERVENTIONAL          PHASE1  \n",
       "NCT03999021            2023-10-10  INTERVENTIONAL          PHASE1  \n",
       "NCT03063021            2022-09-19  INTERVENTIONAL          PHASE1  \n",
       "NCT06067061            2024-05-30  INTERVENTIONAL  PHASE1, PHASE2  \n",
       "NCT04006457            2023-12-22  INTERVENTIONAL          PHASE3  \n",
       "NCT06163326            2024-06-26  INTERVENTIONAL          PHASE3  \n",
       "NCT05879458            2024-05-07  INTERVENTIONAL          PHASE2  \n",
       "NCT05128058            2023-11-13  INTERVENTIONAL          PHASE1  \n",
       "NCT05743244            2024-05-24  INTERVENTIONAL          PHASE2  \n",
       "NCT05852340            2023-08-02  INTERVENTIONAL          PHASE1  \n",
       "NCT04655040            2021-03-18  INTERVENTIONAL          PHASE1  \n",
       "NCT06172348            2024-04-04  INTERVENTIONAL          PHASE1  \n",
       "NCT05583526            2024-06-03  INTERVENTIONAL          PHASE3  \n",
       "NCT06373458            2024-06-04  INTERVENTIONAL          PHASE2  \n",
       "NCT05549934            2023-08-14  INTERVENTIONAL          PHASE2  \n",
       "NCT05097716            2023-10-06  INTERVENTIONAL          PHASE1  \n",
       "NCT05040295            2023-08-21  INTERVENTIONAL          PHASE1  \n",
       "NCT04413617            2023-04-07  INTERVENTIONAL          PHASE2  \n",
       "NCT04517864            2024-06-18  INTERVENTIONAL          PHASE2  \n",
       "NCT03732807            2022-02-24  INTERVENTIONAL  PHASE2, PHASE3  \n",
       "NCT06072183            2024-06-26  INTERVENTIONAL          PHASE3  \n",
       "NCT05636293            2024-02-28  INTERVENTIONAL          PHASE2  \n",
       "NCT05650333            2023-08-25  INTERVENTIONAL          PHASE1  \n",
       "NCT06369454            2024-06-27  INTERVENTIONAL          PHASE1  \n",
       "NCT06450366            2024-06-10  INTERVENTIONAL          PHASE3  \n",
       "NCT05934292            2024-02-07  INTERVENTIONAL          PHASE1  \n",
       "NCT05261126            2023-12-06  INTERVENTIONAL          PHASE2  \n",
       "NCT05070390            2023-05-23  INTERVENTIONAL          PHASE1  \n",
       "NCT05952869            2024-03-13  INTERVENTIONAL          PHASE3  \n",
       "NCT05952856            2024-05-17  INTERVENTIONAL          PHASE3  \n",
       "NCT06008756            2024-06-21  INTERVENTIONAL          PHASE3  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import requests\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "import openpyxl\n",
    "import os \n",
    "\n",
    "# Read in list of assets of interest and convert to list\n",
    "assetFrame = pd.read_excel('assetList2.xlsx')\n",
    "assetList = assetFrame['Asset'].tolist()\n",
    "print('Asset list successfully imported')\n",
    "\n",
    "# Initialize an empty list to store the data\n",
    "data_list = []\n",
    "\n",
    "for asset in assetList:\n",
    "\n",
    "    # Initial URL for the first API call\n",
    "    base_url = \"https://clinicaltrials.gov/api/v2/studies\"\n",
    "    params = {\n",
    "        \"query.term\": asset,\n",
    "        \"pageSize\": 100\n",
    "    }\n",
    "    # Assign asset name from parameter\n",
    "    assetName = params['query.term']\n",
    "\n",
    "    # Loop until there is no nextPageToken\n",
    "    while True:\n",
    "        # Print the current URL (for debugging purposes); Access by looping parameters\n",
    "        print(\"Fetching data from:\", base_url + '?' + '&'.join([f\"{k}={v}\" for k, v in params.items()]))\n",
    "        \n",
    "        # Send a GET request to the API\n",
    "        response = requests.get(base_url, params=params)\n",
    "\n",
    "        # Check if the request was successful\n",
    "        if response.status_code == 200:\n",
    "            data = response.json()  # Parse JSON response\n",
    "            studies = data.get('studies', [])  # Extract the list of studies, pass empty parameters\n",
    "\n",
    "            # Loop through each study and extract specific information\n",
    "            for study in studies:\n",
    "                # Safely access nested keys, Indicates Unknown if unavailable \n",
    "                nctId = study['protocolSection']['identificationModule'].get('nctId', 'Unknown')\n",
    "                studyTitle = study['protocolSection']['identificationModule'].get('officialTitle', 'Unknown')\n",
    "                sponsor = study['protocolSection']['sponsorCollaboratorsModule'].get('leadSponsor', {}).get('name', 'Unknonw Lead Sponsor')\n",
    "                overallStatus = study['protocolSection']['statusModule'].get('overallStatus', 'Unknown')\n",
    "                enrollment = study['protocolSection']['designModule'].get('enrollmentInfo',{}).get('count', 'Unknown')\n",
    "                startDate = study['protocolSection']['statusModule'].get('startDateStruct', {}).get('date', 'Unknown Date')\n",
    "                conditions = ', '.join(study['protocolSection']['conditionsModule'].get('conditions', ['No conditions listed']))\n",
    "                acronym = study['protocolSection']['identificationModule'].get('acronym', 'Unknown')\n",
    "\n",
    "                # Extract interventions safely\n",
    "                interventions_list = study['protocolSection'].get('armsInterventionsModule', {}).get('interventions', [])\n",
    "                interventions = ', '.join([intervention.get('name', 'No intervention name listed') for intervention in interventions_list]) if interventions_list else \"No interventions listed\"\n",
    "\n",
    "                # Extract outcomes safely\n",
    "                primaryOutcomes_list = study['protocolSection'].get('outcomesModule', {}).get('primaryOutcomes', [])\n",
    "                primaryOutcomes = ', '.join([measure.get('measure', 'No primary outcome indicated') for measure in primaryOutcomes_list]) if primaryOutcomes_list else \"No primary outcomes listed\"\n",
    "                secondaryOutcomes_list = study['protocolSection'].get('outcomesModule', {}).get('secondaryOutcomes', [])\n",
    "                secondaryOutcomes = ', '.join([measure.get('measure', 'No secomdary outcomes indicated') for measure in secondaryOutcomes_list]) if secondaryOutcomes_list else \"No secondary outcomes listed\"\n",
    "                \n",
    "                # Extract locations safely\n",
    "                locations_list = study['protocolSection'].get('contactsLocationsModule', {}).get('locations', [])\n",
    "                locations = ', '.join([f\"{location.get('city', 'No City')} - {location.get('country', 'No Country')}\" for location in locations_list]) if locations_list else \"No locations listed\"\n",
    "                \n",
    "                # Extract dates and phases\n",
    "                primaryCompletionDate = study['protocolSection']['statusModule'].get('primaryCompletionDateStruct', {}).get('date', 'Unknown Date')\n",
    "                studyFirstPostDate = study['protocolSection']['statusModule'].get('studyFirstPostDateStruct', {}).get('date', 'Unknown Date')\n",
    "                lastUpdatePostDate = study['protocolSection']['statusModule'].get('lastUpdatePostDateStruct', {}).get('date', 'Unknown Date')\n",
    "                studyType = study['protocolSection']['designModule'].get('studyType', 'Unknown')\n",
    "                phases = ', '.join(study['protocolSection']['designModule'].get('phases', ['Not Available']))\n",
    "\n",
    "                # Append the data to the list as a dictionary\n",
    "                data_list.append({\n",
    "                    \"NCT ID\": nctId,\n",
    "                    \"Asset\": assetName,\n",
    "                    \"Title\": studyTitle,\n",
    "                    \"Lead Sponsor\": sponsor,\n",
    "                    \"Acronym\": acronym,\n",
    "                    \"Overall Status\": overallStatus,\n",
    "                    \"Enrollment\": enrollment,\n",
    "                    \"Start Date\": startDate,\n",
    "                    \"Conditions\": conditions,\n",
    "                    \"Interventions\": interventions,\n",
    "                    \"Primary Outcome(s)\": primaryOutcomes,\n",
    "                    \"Secondary Outcome(s)\": secondaryOutcomes,\n",
    "                    \"Locations\": locations,\n",
    "                    \"Primary Completion Date\": primaryCompletionDate,\n",
    "                    \"Study First Post Date\": studyFirstPostDate,\n",
    "                    \"Last Update Post Date\": lastUpdatePostDate,\n",
    "                    \"Study Type\": studyType,\n",
    "                    \"Phases\": phases\n",
    "                })\n",
    "\n",
    "            # Check for nextPageToken and update the params or break the loop\n",
    "            nextPageToken = data.get('nextPageToken')\n",
    "            if nextPageToken:\n",
    "                params['pageToken'] = nextPageToken  # Set the pageToken for the next request\n",
    "            else:\n",
    "                break  # Exit the loop if no nextPageToken is present\n",
    "        else:\n",
    "            print(\"Failed to fetch data. Status code:\", response.status_code)\n",
    "            break\n",
    "\n",
    "# Create a DataFrame from the list of dictionaries\n",
    "currentDataFrame = pd.DataFrame(data_list)\n",
    "\n",
    "# Identify whether comparator trials excel exists\n",
    "workingDirectory = os.getcwd()\n",
    "isExisting = os.path.exists(workingDirectory+'/oldClinicalTrialsData.csv')\n",
    "\n",
    "# If comparator trial exists already make comparator data frame, otherwise initialize excel\n",
    "if isExisting == True:\n",
    "\n",
    "    # Creating old data frame from existing excel\n",
    "    oldDataDirectory = workingDirectory+'/oldClinicalTrialsData.csv'\n",
    "    oldDataFrame = pd.read_csv(oldDataDirectory)\n",
    "    print('Historic clinical trials data recognized and reconciling changes from historic file and new trial updates.')\n",
    "\n",
    "    # Concatenate old and new data frames based on NCT ID index and swap to be side by side\n",
    "    concatenateFrames = pd.concat([oldDataFrame.set_index('NCT ID'), currentDataFrame.set_index('NCT ID')], \n",
    "            axis='columns', keys=['Old CT Data', 'New CT Data'])\n",
    "    easyCompareFrames = concatenateFrames.swaplevel(axis='columns')[oldDataFrame.columns[1:]]\n",
    "    display(easyCompareFrames)\n",
    "\n",
    "    # Index old and new dataframes on NCT ID\n",
    "    oldDataFrame.set_index('NCT ID', inplace = True)\n",
    "    currentDataFrame.set_index('NCT ID', inplace = True)\n",
    "\n",
    "    # Create dataframes for rows that were added or deleted \n",
    "    addedRows = currentDataFrame[~currentDataFrame.index.isin(oldDataFrame.index)]\n",
    "    deletedRows = oldDataFrame[~oldDataFrame.index.isin(currentDataFrame.index)]\n",
    "    \n",
    "    # Find modified rows\n",
    "    common_index = oldDataFrame.index.intersection(currentDataFrame.index)\n",
    "    modified_rows = oldDataFrame.loc[common_index] != currentDataFrame.loc[common_index]\n",
    "    modified_rows = modified_rows[modified_rows.any(axis=1)]\n",
    "    modified_rows = currentDataFrame.loc[modified_rows.index]\n",
    "\n",
    "    # Display results\n",
    "    print(\"Added rows:\\n\")\n",
    "    display(addedRows)\n",
    "    print(\"\\nDeleted rows:\\n\")\n",
    "    display(deletedRows)\n",
    "    print(\"\\nModified rows:\\n\")\n",
    "    display(modified_rows) #Need to fix modified rows\n",
    "\n",
    "    # For assets that are in both frames, identify when new NCTs have been added, NCTs have changed, and deleted and highlight \n",
    "    # Flag trials that are associated from new asset adds and remove\n",
    "    # Identify where enrollment, start, completion date change\n",
    "\n",
    "else:\n",
    "\n",
    "    # Alerting user that no historic file was found\n",
    "    print('No historic clinical trials data is recognized. We are iniitializing a new file for tracking.')\n",
    "\n",
    "    # Saving new data frame as a csv\n",
    "    currentDataFrame.to_csv(\"oldClinicalTrialsData.csv\", index=False)\n",
    "\n",
    "    # Print the DataFrame\n",
    "    display(currentDataFrame)\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3.8.6 64-bit",
   "metadata": {
    "interpreter": {
     "hash": "aee8b7b246df8f9039afb4144a1f6fd8d2ca17a180786b69acc140d282b71a49"
    }
   },
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.4"
  },
  "orig_nbformat": 2
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
